CN111971035A - 生酮饮食相容的芬氟拉明制剂 - Google Patents
生酮饮食相容的芬氟拉明制剂 Download PDFInfo
- Publication number
- CN111971035A CN111971035A CN201880076100.9A CN201880076100A CN111971035A CN 111971035 A CN111971035 A CN 111971035A CN 201880076100 A CN201880076100 A CN 201880076100A CN 111971035 A CN111971035 A CN 111971035A
- Authority
- CN
- China
- Prior art keywords
- formulation
- fenfluramine
- patient
- syndrome
- epilepsy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 185
- 238000009472 formulation Methods 0.000 title claims abstract description 155
- DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 title claims abstract description 147
- 229960001582 fenfluramine Drugs 0.000 title claims abstract description 114
- 235000020887 ketogenic diet Nutrition 0.000 title claims abstract description 67
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 90
- 230000001037 epileptic effect Effects 0.000 claims abstract description 22
- 239000003755 preservative agent Substances 0.000 claims description 70
- 230000002335 preservative effect Effects 0.000 claims description 58
- 235000014633 carbohydrates Nutrition 0.000 claims description 47
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 47
- 150000001720 carbohydrates Chemical class 0.000 claims description 46
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 35
- 229960001877 fenfluramine hydrochloride Drugs 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 30
- 239000000796 flavoring agent Substances 0.000 claims description 29
- 239000002562 thickening agent Substances 0.000 claims description 26
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 25
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 24
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 23
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 23
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 23
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 22
- 229960002216 methylparaben Drugs 0.000 claims description 22
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 21
- 150000003839 salts Chemical class 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- 239000002253 acid Substances 0.000 claims description 17
- 235000013355 food flavoring agent Nutrition 0.000 claims description 16
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 15
- 239000004376 Sucralose Substances 0.000 claims description 15
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 15
- 235000019408 sucralose Nutrition 0.000 claims description 15
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 15
- 239000013543 active substance Substances 0.000 claims description 14
- 229940071826 hydroxyethyl cellulose Drugs 0.000 claims description 14
- 230000001965 increasing effect Effects 0.000 claims description 13
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 13
- 239000006172 buffering agent Substances 0.000 claims description 11
- 235000019788 craving Nutrition 0.000 claims description 11
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 11
- QYNMSPKSYXPZHG-UHFFFAOYSA-M sodium;4-ethoxycarbonylphenolate Chemical compound [Na+].CCOC(=O)C1=CC=C([O-])C=C1 QYNMSPKSYXPZHG-UHFFFAOYSA-M 0.000 claims description 10
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 10
- 229920001285 xanthan gum Polymers 0.000 claims description 10
- 235000010493 xanthan gum Nutrition 0.000 claims description 10
- 239000000230 xanthan gum Substances 0.000 claims description 10
- 229940082509 xanthan gum Drugs 0.000 claims description 10
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 9
- 241000167854 Bourreria succulenta Species 0.000 claims description 8
- 208000001654 Drug Resistant Epilepsy Diseases 0.000 claims description 8
- 235000019693 cherries Nutrition 0.000 claims description 8
- 239000012669 liquid formulation Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 206010056465 Food craving Diseases 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 claims description 5
- 229960002303 citric acid monohydrate Drugs 0.000 claims description 5
- 235000011194 food seasoning agent Nutrition 0.000 claims description 5
- 229940050931 potassium citrate monohydrate Drugs 0.000 claims description 5
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 5
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 5
- 229960003415 propylparaben Drugs 0.000 claims description 5
- 235000016623 Fragaria vesca Nutrition 0.000 claims description 4
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims description 4
- 239000013011 aqueous formulation Substances 0.000 claims description 4
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims description 4
- 235000012054 meals Nutrition 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 235000010199 sorbic acid Nutrition 0.000 claims description 4
- 239000004334 sorbic acid Substances 0.000 claims description 4
- 229940075582 sorbic acid Drugs 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 3
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 240000009088 Fragaria x ananassa Species 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 229920001531 copovidone Polymers 0.000 claims description 3
- 235000010241 potassium sorbate Nutrition 0.000 claims description 3
- 239000004302 potassium sorbate Substances 0.000 claims description 3
- 229940069338 potassium sorbate Drugs 0.000 claims description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 3
- 235000010234 sodium benzoate Nutrition 0.000 claims description 3
- 239000004299 sodium benzoate Substances 0.000 claims description 3
- 244000215068 Acacia senegal Species 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 235000009754 Vitis X bourquina Nutrition 0.000 claims description 2
- 235000012333 Vitis X labruscana Nutrition 0.000 claims description 2
- 240000006365 Vitis vinifera Species 0.000 claims description 2
- 235000014787 Vitis vinifera Nutrition 0.000 claims description 2
- 235000010489 acacia gum Nutrition 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- PJAHUDTUZRZBKM-UHFFFAOYSA-K potassium citrate monohydrate Chemical group O.[K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PJAHUDTUZRZBKM-UHFFFAOYSA-K 0.000 claims 2
- 235000005976 Citrus sinensis Nutrition 0.000 claims 1
- 240000002319 Citrus sinensis Species 0.000 claims 1
- 229920000161 Locust bean gum Polymers 0.000 claims 1
- 235000011034 Rubus glaucus Nutrition 0.000 claims 1
- 244000235659 Rubus idaeus Species 0.000 claims 1
- 235000009122 Rubus idaeus Nutrition 0.000 claims 1
- 229960004543 anhydrous citric acid Drugs 0.000 claims 1
- 229960004365 benzoic acid Drugs 0.000 claims 1
- 235000021028 berry Nutrition 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 235000010420 locust bean gum Nutrition 0.000 claims 1
- 239000000711 locust bean gum Substances 0.000 claims 1
- 229910000160 potassium phosphate Inorganic materials 0.000 claims 1
- 229940093916 potassium phosphate Drugs 0.000 claims 1
- 235000011009 potassium phosphates Nutrition 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 229940095574 propionic acid Drugs 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 229960003885 sodium benzoate Drugs 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 abstract description 59
- 238000000034 method Methods 0.000 abstract description 42
- 208000024891 symptom Diseases 0.000 abstract description 3
- 206010015037 epilepsy Diseases 0.000 description 48
- 239000003814 drug Substances 0.000 description 35
- 239000000825 pharmaceutical preparation Substances 0.000 description 32
- 235000003599 food sweetener Nutrition 0.000 description 30
- 239000003765 sweetening agent Substances 0.000 description 30
- 235000005911 diet Nutrition 0.000 description 29
- 239000000243 solution Substances 0.000 description 29
- 230000037213 diet Effects 0.000 description 28
- 229940127557 pharmaceutical product Drugs 0.000 description 25
- 230000035772 mutation Effects 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 23
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 22
- -1 UBE3 Proteins 0.000 description 22
- 229940079593 drug Drugs 0.000 description 22
- 239000000546 pharmaceutical excipient Substances 0.000 description 22
- 238000003860 storage Methods 0.000 description 21
- 229940100688 oral solution Drugs 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 238000011161 development Methods 0.000 description 17
- 230000018109 developmental process Effects 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000007774 longterm Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000002560 therapeutic procedure Methods 0.000 description 16
- 239000002552 dosage form Substances 0.000 description 15
- 239000008186 active pharmaceutical agent Substances 0.000 description 14
- 239000007864 aqueous solution Substances 0.000 description 14
- 239000003981 vehicle Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 208000035475 disorder Diseases 0.000 description 13
- 235000019634 flavors Nutrition 0.000 description 13
- 238000001556 precipitation Methods 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 11
- 229960004106 citric acid Drugs 0.000 description 11
- 229940124597 therapeutic agent Drugs 0.000 description 11
- 239000001961 anticonvulsive agent Substances 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 229940088679 drug related substance Drugs 0.000 description 10
- 159000000000 sodium salts Chemical class 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 239000002245 particle Substances 0.000 description 9
- 239000001508 potassium citrate Substances 0.000 description 9
- 235000019640 taste Nutrition 0.000 description 9
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
- 150000002576 ketones Chemical class 0.000 description 8
- 239000008297 liquid dosage form Substances 0.000 description 8
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 7
- 239000001913 cellulose Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 229930195712 glutamate Natural products 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000030159 metabolic disease Diseases 0.000 description 7
- 235000019629 palatability Nutrition 0.000 description 7
- 229920000642 polymer Polymers 0.000 description 7
- 230000002265 prevention Effects 0.000 description 7
- DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 description 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- 208000002091 Febrile Seizures Diseases 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229960004597 dexfenfluramine Drugs 0.000 description 6
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 150000005204 hydroxybenzenes Chemical class 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 230000002361 ketogenic effect Effects 0.000 description 6
- 238000013546 non-drug therapy Methods 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 229960002635 potassium citrate Drugs 0.000 description 6
- 235000011082 potassium citrates Nutrition 0.000 description 6
- 208000005809 status epilepticus Diseases 0.000 description 6
- 229960001897 stiripentol Drugs 0.000 description 6
- IBLNKMRFIPWSOY-FNORWQNLSA-N stiripentol Chemical compound CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1 IBLNKMRFIPWSOY-FNORWQNLSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 229920002752 Konjac Polymers 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 208000003554 absence epilepsy Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000007857 degradation product Substances 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 229940126534 drug product Drugs 0.000 description 5
- 201000009028 early myoclonic encephalopathy Diseases 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 229960003742 phenol Drugs 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 229940032147 starch Drugs 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 4
- 102100036846 C-C motif chemokine 21 Human genes 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 4
- 206010071082 Juvenile myoclonic epilepsy Diseases 0.000 description 4
- 208000007976 Ketosis Diseases 0.000 description 4
- 229920003082 Povidone K 90 Polymers 0.000 description 4
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 description 4
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- WDJHALXBUFZDSR-UHFFFAOYSA-M acetoacetate Chemical compound CC(=O)CC([O-])=O WDJHALXBUFZDSR-UHFFFAOYSA-M 0.000 description 4
- 229960003965 antiepileptics Drugs 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000012395 formulation development Methods 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000002641 glycemic effect Effects 0.000 description 4
- 208000034287 idiopathic generalized susceptibility to 7 epilepsy Diseases 0.000 description 4
- 239000000252 konjac Substances 0.000 description 4
- 238000007726 management method Methods 0.000 description 4
- 230000000873 masking effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 239000008363 phosphate buffer Substances 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 description 3
- 102000014817 CACNA1A Human genes 0.000 description 3
- 101000923091 Danio rerio Aristaless-related homeobox protein Proteins 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- 208000002877 Epileptic Syndromes Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102100031470 Homeobox protein ARX Human genes 0.000 description 3
- 101000923090 Homo sapiens Homeobox protein ARX Proteins 0.000 description 3
- 101000927773 Homo sapiens Rho guanine nucleotide exchange factor 9 Proteins 0.000 description 3
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 3
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 description 3
- 101000935117 Homo sapiens Voltage-dependent P/Q-type calcium channel subunit alpha-1A Proteins 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 201000008189 Juvenile absence epilepsy Diseases 0.000 description 3
- 101150083522 MECP2 gene Proteins 0.000 description 3
- 102100039124 Methyl-CpG-binding protein 2 Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100033221 Rho guanine nucleotide exchange factor 9 Human genes 0.000 description 3
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 3
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000001773 anti-convulsant effect Effects 0.000 description 3
- 239000008135 aqueous vehicle Substances 0.000 description 3
- 201000010295 benign neonatal seizures Diseases 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 229960004926 chlorobutanol Drugs 0.000 description 3
- 229960001403 clobazam Drugs 0.000 description 3
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000013325 dietary fiber Nutrition 0.000 description 3
- 235000013804 distarch phosphate Nutrition 0.000 description 3
- 239000001245 distarch phosphate Substances 0.000 description 3
- 238000002651 drug therapy Methods 0.000 description 3
- 230000000763 evoking effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000021472 generally recognized as safe Nutrition 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000004140 ketosis Effects 0.000 description 3
- 235000019823 konjac gum Nutrition 0.000 description 3
- 229960001848 lamotrigine Drugs 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 3
- 230000000050 nutritive effect Effects 0.000 description 3
- 239000006186 oral dosage form Substances 0.000 description 3
- 239000007968 orange flavor Substances 0.000 description 3
- 239000003002 pH adjusting agent Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- ZLVSYODPTJZFMK-UHFFFAOYSA-M sodium 4-hydroxybenzoate Chemical compound [Na+].OC1=CC=C(C([O-])=O)C=C1 ZLVSYODPTJZFMK-UHFFFAOYSA-M 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 201000008914 temporal lobe epilepsy Diseases 0.000 description 3
- 235000015870 tripotassium citrate Nutrition 0.000 description 3
- 229940102566 valproate Drugs 0.000 description 3
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 2
- WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 2
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 2
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920000107 Acetylated distarch adipate Polymers 0.000 description 2
- 102100024085 Alpha-aminoadipic semialdehyde dehydrogenase Human genes 0.000 description 2
- 208000002381 Brain Hypoxia Diseases 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- 108050001186 Chaperonin Cpn60 Proteins 0.000 description 2
- 102000052603 Chaperonins Human genes 0.000 description 2
- 201000001913 Childhood absence epilepsy Diseases 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 102100034746 Cyclin-dependent kinase-like 5 Human genes 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 102000017703 GABRG2 Human genes 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 2
- 229920000569 Gum karaya Polymers 0.000 description 2
- 206010019196 Head injury Diseases 0.000 description 2
- 206010019468 Hemiplegia Diseases 0.000 description 2
- 101000690235 Homo sapiens Alpha-aminoadipic semialdehyde dehydrogenase Proteins 0.000 description 2
- 101000945692 Homo sapiens Cyclin-dependent kinase-like 5 Proteins 0.000 description 2
- 101000926813 Homo sapiens Gamma-aminobutyric acid receptor subunit gamma-2 Proteins 0.000 description 2
- 101001125242 Homo sapiens Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 description 2
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 2
- 101001094809 Homo sapiens Polynucleotide 5'-hydroxyl-kinase Proteins 0.000 description 2
- 101001072243 Homo sapiens Protocadherin-19 Proteins 0.000 description 2
- 101001120726 Homo sapiens Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial Proteins 0.000 description 2
- 101001099922 Homo sapiens Retinoic acid-induced protein 1 Proteins 0.000 description 2
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 2
- 101000658622 Homo sapiens Testis-specific Y-encoded-like protein 2 Proteins 0.000 description 2
- 101000983947 Homo sapiens Voltage-dependent L-type calcium channel subunit beta-4 Proteins 0.000 description 2
- 206010021750 Infantile Spasms Diseases 0.000 description 2
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 208000015439 Lysosomal storage disease Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 101800000990 PEX Proteins 0.000 description 2
- 206010061334 Partial seizures Diseases 0.000 description 2
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 2
- 102100035153 Phosphate-regulating neutral endopeptidase PHEX Human genes 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 102100035460 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 208000033063 Progressive myoclonic epilepsy Diseases 0.000 description 2
- 102100036389 Protocadherin-19 Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 102100026067 Pyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrial Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102100038470 Retinoic acid-induced protein 1 Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 208000004974 Rolandic Epilepsy Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000934878 Sterculia Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102100034917 Testis-specific Y-encoded-like protein 2 Human genes 0.000 description 2
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 2
- 102000001763 Vesicular Glutamate Transport Proteins Human genes 0.000 description 2
- 108010040170 Vesicular Glutamate Transport Proteins Proteins 0.000 description 2
- 102100025836 Voltage-dependent L-type calcium channel subunit beta-4 Human genes 0.000 description 2
- 201000006791 West syndrome Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 208000012471 X-linked intellectual disability Diseases 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 2
- 235000013770 acetylated oxidized starch Nutrition 0.000 description 2
- 239000001073 acetylated oxidized starch Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000010407 ammonium alginate Nutrition 0.000 description 2
- 239000000728 ammonium alginate Substances 0.000 description 2
- KPGABFJTMYCRHJ-YZOKENDUSA-N ammonium alginate Chemical compound [NH4+].[NH4+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O KPGABFJTMYCRHJ-YZOKENDUSA-N 0.000 description 2
- 230000000578 anorexic effect Effects 0.000 description 2
- 230000002082 anti-convulsion Effects 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 201000003452 benign familial neonatal epilepsy Diseases 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- 150000001557 benzodiazepines Chemical class 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960003168 bronopol Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000008364 bulk solution Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 229940067596 butylparaben Drugs 0.000 description 2
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 2
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229960000623 carbamazepine Drugs 0.000 description 2
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 108010079058 casein hydrolysate Proteins 0.000 description 2
- 229960002798 cetrimide Drugs 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000007958 cherry flavor Substances 0.000 description 2
- 208000033205 childhood epilepsy with centrotemporal spikes Diseases 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 2
- 229960003120 clonazepam Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical class OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 229960003529 diazepam Drugs 0.000 description 2
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 229960002767 ethosuximide Drugs 0.000 description 2
- HAPOVYFOVVWLRS-UHFFFAOYSA-N ethosuximide Chemical compound CCC1(C)CC(=O)NC1=O HAPOVYFOVVWLRS-UHFFFAOYSA-N 0.000 description 2
- 206010016284 febrile convulsion Diseases 0.000 description 2
- 238000012495 forced degradation study Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000010492 gellan gum Nutrition 0.000 description 2
- 239000000216 gellan gum Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 229940113174 imidurea Drugs 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 235000010494 karaya gum Nutrition 0.000 description 2
- 239000000231 karaya gum Substances 0.000 description 2
- 229940039371 karaya gum Drugs 0.000 description 2
- 208000036546 leukodystrophy Diseases 0.000 description 2
- 229960004002 levetiracetam Drugs 0.000 description 2
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000012263 liquid product Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229960004391 lorazepam Drugs 0.000 description 2
- 230000036244 malformation Effects 0.000 description 2
- 235000010449 maltitol Nutrition 0.000 description 2
- 239000000845 maltitol Substances 0.000 description 2
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 2
- 229940035436 maltitol Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 2
- 229960003793 midazolam Drugs 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 235000013807 monostarch phosphate Nutrition 0.000 description 2
- 239000001248 monostarch phosphate Substances 0.000 description 2
- 235000021096 natural sweeteners Nutrition 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 238000011457 non-pharmacological treatment Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 229960001816 oxcarbazepine Drugs 0.000 description 2
- CTRLABGOLIVAIY-UHFFFAOYSA-N oxcarbazepine Chemical compound C1C(=O)C2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 CTRLABGOLIVAIY-UHFFFAOYSA-N 0.000 description 2
- 230000009984 peri-natal effect Effects 0.000 description 2
- 210000002824 peroxisome Anatomy 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 229940096826 phenylmercuric acetate Drugs 0.000 description 2
- 229960002036 phenytoin Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 2
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000010421 processed eucheuma seaweed Nutrition 0.000 description 2
- 201000001204 progressive myoclonus epilepsy Diseases 0.000 description 2
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 2
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 2
- 208000002815 pulmonary hypertension Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 201000005070 reflex epilepsy Diseases 0.000 description 2
- 235000019643 salty taste Nutrition 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000031906 susceptibility to X-linked 2 autism Diseases 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 235000010491 tara gum Nutrition 0.000 description 2
- 239000000213 tara gum Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229960004394 topiramate Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 229960001722 verapamil Drugs 0.000 description 2
- 229960005318 vigabatrin Drugs 0.000 description 2
- PJDFLNIOAUIZSL-UHFFFAOYSA-N vigabatrin Chemical compound C=CC(N)CCC(O)=O PJDFLNIOAUIZSL-UHFFFAOYSA-N 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- XOYCLJDJUKHHHS-LHBOOPKSSA-N (2s,3s,4s,5r,6r)-6-[[(2s,3s,5r)-3-amino-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@H](O2)C(O)=O)O)[C@@H](N)C1 XOYCLJDJUKHHHS-LHBOOPKSSA-N 0.000 description 1
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 102100030390 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Human genes 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- IXQGCWUGDFDQMF-UHFFFAOYSA-N 2-Ethylphenol Chemical class CCC1=CC=CC=C1O IXQGCWUGDFDQMF-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- 102100039358 3-hydroxyacyl-CoA dehydrogenase type-2 Human genes 0.000 description 1
- OZIZXEZZMVXSMQ-UHFFFAOYSA-N 3-oxobutanoic acid Chemical compound CC(=O)CC(O)=O.CC(=O)CC(O)=O OZIZXEZZMVXSMQ-UHFFFAOYSA-N 0.000 description 1
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 description 1
- 102100035923 4-aminobutyrate aminotransferase, mitochondrial Human genes 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 1
- GUOCOOQWZHQBJI-UHFFFAOYSA-N 4-oct-7-enoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OCCCCCCC=C GUOCOOQWZHQBJI-UHFFFAOYSA-N 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 102100037991 85/88 kDa calcium-independent phospholipase A2 Human genes 0.000 description 1
- 101150077457 ACOX1 gene Proteins 0.000 description 1
- 102100033477 ADP-ribosylation factor-like protein 13A Human genes 0.000 description 1
- 101150012579 ADSL gene Proteins 0.000 description 1
- 102100027573 ATP synthase subunit alpha, mitochondrial Human genes 0.000 description 1
- 102100021176 ATP-sensitive inward rectifier potassium channel 10 Human genes 0.000 description 1
- 101150091481 ATP7 gene Proteins 0.000 description 1
- 101150020330 ATRX gene Proteins 0.000 description 1
- 102100022117 Abnormal spindle-like microcephaly-associated protein Human genes 0.000 description 1
- 206010000349 Acanthosis Diseases 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 102100020775 Adenylosuccinate lyase Human genes 0.000 description 1
- 108700040193 Adenylosuccinate lyases Proteins 0.000 description 1
- 102100036799 Adhesion G-protein coupled receptor V1 Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100022622 Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Human genes 0.000 description 1
- 102100035028 Alpha-L-iduronidase Human genes 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 229930182536 Antimycin Natural products 0.000 description 1
- 101100232079 Arabidopsis thaliana HSR4 gene Proteins 0.000 description 1
- 101100455868 Arabidopsis thaliana MKK2 gene Proteins 0.000 description 1
- 239000001904 Arabinogalactan Substances 0.000 description 1
- 229920000189 Arabinogalactan Polymers 0.000 description 1
- 102100036131 Arginine-tRNA ligase, cytoplasmic Human genes 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010003628 Atonic seizures Diseases 0.000 description 1
- 208000017785 Autosomal dominant epilepsy with auditory features Diseases 0.000 description 1
- 208000000848 Autosomal recessive primary microcephaly Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 101150007734 BCS1 gene Proteins 0.000 description 1
- 206010070530 Benign rolandic epilepsy Diseases 0.000 description 1
- 102100026031 Beta-glucuronidase Human genes 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 102100022549 Beta-hexosaminidase subunit beta Human genes 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- 239000004370 Bleached starch Substances 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102000014835 CACNA1H Human genes 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000001736 Calcium glycerylphosphate Substances 0.000 description 1
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 1
- 102100023073 Calcium-activated potassium channel subunit alpha-1 Human genes 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100032219 Cathepsin D Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 101100498752 Cavia porcellus DCXR gene Proteins 0.000 description 1
- 102100031667 Cell adhesion molecule-related/down-regulated by oncogenes Human genes 0.000 description 1
- 102100023441 Centromere protein J Human genes 0.000 description 1
- 102100023309 Centrosomal protein of 152 kDa Human genes 0.000 description 1
- 101710181192 Centrosomal protein of 152 kDa Proteins 0.000 description 1
- 102100035673 Centrosomal protein of 290 kDa Human genes 0.000 description 1
- 101710198317 Centrosomal protein of 290 kDa Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- 102100023509 Chloride channel protein 2 Human genes 0.000 description 1
- 102100031265 Chromodomain-helicase-DNA-binding protein 2 Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 244000241235 Citrullus lanatus Species 0.000 description 1
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102100024342 Contactin-2 Human genes 0.000 description 1
- 102100040499 Contactin-associated protein-like 2 Human genes 0.000 description 1
- 208000032065 Convulsion neonatal Diseases 0.000 description 1
- 108010022637 Copper-Transporting ATPases Proteins 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 241000544061 Cuculus canorus Species 0.000 description 1
- 102100028901 Cullin-4B Human genes 0.000 description 1
- 102100023381 Cyanocobalamin reductase / alkylcobalamin dealkylase Human genes 0.000 description 1
- 101710164985 Cyanocobalamin reductase / alkylcobalamin dealkylase Proteins 0.000 description 1
- SXVPOSFURRDKBO-UHFFFAOYSA-N Cyclododecanone Chemical compound O=C1CCCCCCCCCCC1 SXVPOSFURRDKBO-UHFFFAOYSA-N 0.000 description 1
- 102100026891 Cystatin-B Human genes 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 102100034690 Delta(14)-sterol reductase LBR Human genes 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 102100034289 Deoxynucleoside triphosphate triphosphohydrolase SAMHD1 Human genes 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102100023319 Dihydrolipoyl dehydrogenase, mitochondrial Human genes 0.000 description 1
- 102100022334 Dihydropyrimidine dehydrogenase [NADP(+)] Human genes 0.000 description 1
- 235000017274 Diospyros sandwicensis Nutrition 0.000 description 1
- 102100031605 Dolichol kinase Human genes 0.000 description 1
- 102100031477 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit Human genes 0.000 description 1
- 101100108136 Drosophila melanogaster Adck1 gene Proteins 0.000 description 1
- 102100028554 Dual specificity tyrosine-phosphorylation-regulated kinase 1A Human genes 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102100034745 E3 ubiquitin-protein ligase HERC2 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102100029060 EF-hand domain-containing protein 1 Human genes 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
- 102100030695 Electron transfer flavoprotein subunit alpha, mitochondrial Human genes 0.000 description 1
- 102100027262 Electron transfer flavoprotein subunit beta Human genes 0.000 description 1
- 102100031804 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial Human genes 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 102100030751 Eomesodermin homolog Human genes 0.000 description 1
- 208000024658 Epilepsy syndrome Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 108010082945 Eukaryotic Initiation Factor-2B Proteins 0.000 description 1
- 102100027327 Eukaryotic translation initiation factor 2 subunit 2 Human genes 0.000 description 1
- 102100035650 Extracellular calcium-sensing receptor Human genes 0.000 description 1
- 101710191461 F420-dependent glucose-6-phosphate dehydrogenase Proteins 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 101150026630 FOXG1 gene Proteins 0.000 description 1
- 102100038635 FYVE, RhoGEF and PH domain-containing protein 1 Human genes 0.000 description 1
- 208000026437 Familial focal epilepsy with variable foci Diseases 0.000 description 1
- 208000033497 Familial temporal lobe epilepsy Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 102100026561 Filamin-A Human genes 0.000 description 1
- 102100035139 Folate receptor alpha Human genes 0.000 description 1
- 102100020871 Forkhead box protein G1 Human genes 0.000 description 1
- XWLUWCNOOVRFPX-UHFFFAOYSA-N Fosphenytoin Chemical compound O=C1N(COP(O)(=O)O)C(=O)NC1(C=1C=CC=CC=1)C1=CC=CC=C1 XWLUWCNOOVRFPX-UHFFFAOYSA-N 0.000 description 1
- 244000307700 Fragaria vesca Species 0.000 description 1
- 201000009010 Frontal lobe epilepsy Diseases 0.000 description 1
- 101150096822 Fuca1 gene Proteins 0.000 description 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
- 101710150822 G protein-regulated inducer of neurite outgrowth 1 Proteins 0.000 description 1
- 102000017696 GABRA1 Human genes 0.000 description 1
- 102000017707 GABRB3 Human genes 0.000 description 1
- 102000017706 GABRD Human genes 0.000 description 1
- 102100022688 GATOR complex protein DEPDC5 Human genes 0.000 description 1
- 102100038722 GPI mannosyltransferase 2 Human genes 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 102100039788 GTPase NRas Human genes 0.000 description 1
- 102100028496 Galactocerebrosidase Human genes 0.000 description 1
- 102100034013 Gamma-glutamyl phosphate reductase Human genes 0.000 description 1
- 101710198928 Gamma-glutamyl phosphate reductase Proteins 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 102100034009 Glutamate dehydrogenase 1, mitochondrial Human genes 0.000 description 1
- 102100030669 Glutamate receptor 3 Human genes 0.000 description 1
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 description 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
- 102100039611 Glutamine synthetase Human genes 0.000 description 1
- 102100028603 Glutaryl-CoA dehydrogenase, mitochondrial Human genes 0.000 description 1
- 102100025506 Glycine cleavage system H protein, mitochondrial Human genes 0.000 description 1
- 102100033495 Glycine dehydrogenase (decarboxylating), mitochondrial Human genes 0.000 description 1
- 102100033945 Glycine receptor subunit alpha-1 Human genes 0.000 description 1
- 102100033958 Glycine receptor subunit beta Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 102100032530 Glypican-3 Human genes 0.000 description 1
- 102100024013 Golgi SNAP receptor complex member 2 Human genes 0.000 description 1
- 101710159101 Green-light absorbing proteorhodopsin Proteins 0.000 description 1
- 208000009396 Group II Malformations of Cortical Development Diseases 0.000 description 1
- 102100040579 Guanidinoacetate N-methyltransferase Human genes 0.000 description 1
- 102100031561 Hamartin Human genes 0.000 description 1
- 102100039991 Heparan-alpha-glucosaminide N-acetyltransferase Human genes 0.000 description 1
- 206010063629 Hippocampal sclerosis Diseases 0.000 description 1
- 102100027768 Histone-lysine N-methyltransferase 2D Human genes 0.000 description 1
- 101000583063 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-1 Proteins 0.000 description 1
- 101001035740 Homo sapiens 3-hydroxyacyl-CoA dehydrogenase type-2 Proteins 0.000 description 1
- 101001000686 Homo sapiens 4-aminobutyrate aminotransferase, mitochondrial Proteins 0.000 description 1
- 101000927075 Homo sapiens ADP-ribosylation factor-like protein 13A Proteins 0.000 description 1
- 101000936262 Homo sapiens ATP synthase subunit alpha, mitochondrial Proteins 0.000 description 1
- 101000936965 Homo sapiens ATP synthase-coupling factor 6, mitochondrial Proteins 0.000 description 1
- 101000614696 Homo sapiens ATP-sensitive inward rectifier potassium channel 10 Proteins 0.000 description 1
- 101000900939 Homo sapiens Abnormal spindle-like microcephaly-associated protein Proteins 0.000 description 1
- 101000928167 Homo sapiens Adhesion G-protein coupled receptor V1 Proteins 0.000 description 1
- 101000972916 Homo sapiens Alpha-1,3-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase Proteins 0.000 description 1
- 101001019502 Homo sapiens Alpha-L-iduronidase Proteins 0.000 description 1
- 101000874860 Homo sapiens Arginine-tRNA ligase, cytoplasmic Proteins 0.000 description 1
- 101000923070 Homo sapiens Arylsulfatase B Proteins 0.000 description 1
- 101100004264 Homo sapiens BCS1L gene Proteins 0.000 description 1
- 101000933465 Homo sapiens Beta-glucuronidase Proteins 0.000 description 1
- 101001045440 Homo sapiens Beta-hexosaminidase subunit alpha Proteins 0.000 description 1
- 101001045433 Homo sapiens Beta-hexosaminidase subunit beta Proteins 0.000 description 1
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 1
- 101000777781 Homo sapiens Cell adhesion molecule-related/down-regulated by oncogenes Proteins 0.000 description 1
- 101000907924 Homo sapiens Centromere protein J Proteins 0.000 description 1
- 101000906633 Homo sapiens Chloride channel protein 2 Proteins 0.000 description 1
- 101000777079 Homo sapiens Chromodomain-helicase-DNA-binding protein 2 Proteins 0.000 description 1
- 101000909516 Homo sapiens Contactin-2 Proteins 0.000 description 1
- 101000749877 Homo sapiens Contactin-associated protein-like 2 Proteins 0.000 description 1
- 101000916231 Homo sapiens Cullin-4B Proteins 0.000 description 1
- 101000912191 Homo sapiens Cystatin-B Proteins 0.000 description 1
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 description 1
- 101000945982 Homo sapiens Delta(14)-sterol reductase LBR Proteins 0.000 description 1
- 101000902632 Homo sapiens Dihydropyrimidine dehydrogenase [NADP(+)] Proteins 0.000 description 1
- 101000845698 Homo sapiens Dolichol kinase Proteins 0.000 description 1
- 101001130785 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit Proteins 0.000 description 1
- 101000880945 Homo sapiens Down syndrome cell adhesion molecule Proteins 0.000 description 1
- 101000838016 Homo sapiens Dual specificity tyrosine-phosphorylation-regulated kinase 1A Proteins 0.000 description 1
- 101000872516 Homo sapiens E3 ubiquitin-protein ligase HERC2 Proteins 0.000 description 1
- 101000840938 Homo sapiens EF-hand domain-containing protein 1 Proteins 0.000 description 1
- 101001010541 Homo sapiens Electron transfer flavoprotein subunit alpha, mitochondrial Proteins 0.000 description 1
- 101001057122 Homo sapiens Electron transfer flavoprotein subunit beta Proteins 0.000 description 1
- 101000920874 Homo sapiens Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial Proteins 0.000 description 1
- 101001064167 Homo sapiens Eomesodermin homolog Proteins 0.000 description 1
- 101000866286 Homo sapiens Excitatory amino acid transporter 1 Proteins 0.000 description 1
- 101000913549 Homo sapiens Filamin-A Proteins 0.000 description 1
- 101001023230 Homo sapiens Folate receptor alpha Proteins 0.000 description 1
- 101001044724 Homo sapiens GATOR complex protein DEPDC5 Proteins 0.000 description 1
- 101000604574 Homo sapiens GPI mannosyltransferase 2 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 description 1
- 101000860395 Homo sapiens Galactocerebrosidase Proteins 0.000 description 1
- 101000893331 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-1 Proteins 0.000 description 1
- 101001073597 Homo sapiens Gamma-aminobutyric acid receptor subunit beta-3 Proteins 0.000 description 1
- 101001073587 Homo sapiens Gamma-aminobutyric acid receptor subunit delta Proteins 0.000 description 1
- 101000870042 Homo sapiens Glutamate dehydrogenase 1, mitochondrial Proteins 0.000 description 1
- 101001010434 Homo sapiens Glutamate receptor 3 Proteins 0.000 description 1
- 101000972850 Homo sapiens Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 1
- 101000888841 Homo sapiens Glutamine synthetase Proteins 0.000 description 1
- 101001058943 Homo sapiens Glutaryl-CoA dehydrogenase, mitochondrial Proteins 0.000 description 1
- 101000856845 Homo sapiens Glycine cleavage system H protein, mitochondrial Proteins 0.000 description 1
- 101000998096 Homo sapiens Glycine dehydrogenase (decarboxylating), mitochondrial Proteins 0.000 description 1
- 101000996297 Homo sapiens Glycine receptor subunit alpha-1 Proteins 0.000 description 1
- 101000996225 Homo sapiens Glycine receptor subunit beta Proteins 0.000 description 1
- 101001014668 Homo sapiens Glypican-3 Proteins 0.000 description 1
- 101000904234 Homo sapiens Golgi SNAP receptor complex member 2 Proteins 0.000 description 1
- 101000893897 Homo sapiens Guanidinoacetate N-methyltransferase Proteins 0.000 description 1
- 101000795643 Homo sapiens Hamartin Proteins 0.000 description 1
- 101001035092 Homo sapiens Heparan-alpha-glucosaminide N-acetyltransferase Proteins 0.000 description 1
- 101001008894 Homo sapiens Histone-lysine N-methyltransferase 2D Proteins 0.000 description 1
- 101001077647 Homo sapiens IQ motif and SEC7 domain-containing protein 2 Proteins 0.000 description 1
- 101001077323 Homo sapiens KIF-binding protein Proteins 0.000 description 1
- 101001138081 Homo sapiens L-2-hydroxyglutarate dehydrogenase, mitochondrial Proteins 0.000 description 1
- 101000876418 Homo sapiens Laforin Proteins 0.000 description 1
- 101000882389 Homo sapiens Laforin, isoform 9 Proteins 0.000 description 1
- 101000620451 Homo sapiens Leucine-rich glioma-inactivated protein 1 Proteins 0.000 description 1
- 101001088887 Homo sapiens Lysine-specific demethylase 5C Proteins 0.000 description 1
- 101001122938 Homo sapiens Lysosomal protective protein Proteins 0.000 description 1
- 101000578932 Homo sapiens Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Proteins 0.000 description 1
- 101001013648 Homo sapiens Methionine synthase Proteins 0.000 description 1
- 101001116314 Homo sapiens Methionine synthase reductase Proteins 0.000 description 1
- 101000587058 Homo sapiens Methylenetetrahydrofolate reductase Proteins 0.000 description 1
- 101001074975 Homo sapiens Molybdopterin molybdenumtransferase Proteins 0.000 description 1
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 description 1
- 101001066305 Homo sapiens N-acetylgalactosamine-6-sulfatase Proteins 0.000 description 1
- 101001072470 Homo sapiens N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Proteins 0.000 description 1
- 101000829992 Homo sapiens N-acetylglucosamine-6-sulfatase Proteins 0.000 description 1
- 101000997654 Homo sapiens N-acetylmannosamine kinase Proteins 0.000 description 1
- 101001108436 Homo sapiens Neurexin-1 Proteins 0.000 description 1
- 101001108433 Homo sapiens Neurexin-1-beta Proteins 0.000 description 1
- 101000782865 Homo sapiens Neuronal acetylcholine receptor subunit alpha-2 Proteins 0.000 description 1
- 101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 description 1
- 101000726901 Homo sapiens Neuronal acetylcholine receptor subunit beta-2 Proteins 0.000 description 1
- 101000720704 Homo sapiens Neuronal migration protein doublecortin Proteins 0.000 description 1
- 101000602167 Homo sapiens Neuroserpin Proteins 0.000 description 1
- 101001024120 Homo sapiens Nipped-B-like protein Proteins 0.000 description 1
- 101000979687 Homo sapiens Nuclear distribution protein nudE homolog 1 Proteins 0.000 description 1
- 101001137060 Homo sapiens Oligophrenin-1 Proteins 0.000 description 1
- 101000721946 Homo sapiens Oral-facial-digital syndrome 1 protein Proteins 0.000 description 1
- 101000692980 Homo sapiens PHD finger protein 6 Proteins 0.000 description 1
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 description 1
- 101000981502 Homo sapiens Pantothenate kinase 2, mitochondrial Proteins 0.000 description 1
- 101001117010 Homo sapiens Pericentrin Proteins 0.000 description 1
- 101000922137 Homo sapiens Peripheral plasma membrane protein CASK Proteins 0.000 description 1
- 101001074954 Homo sapiens Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Proteins 0.000 description 1
- 101000611427 Homo sapiens Polyglutamine-binding protein 1 Proteins 0.000 description 1
- 101000944018 Homo sapiens Potassium channel subfamily T member 1 Proteins 0.000 description 1
- 101000994626 Homo sapiens Potassium voltage-gated channel subfamily A member 1 Proteins 0.000 description 1
- 101001088739 Homo sapiens Probable inactive ribonuclease-like protein 12 Proteins 0.000 description 1
- 101000577696 Homo sapiens Proline-rich transmembrane protein 2 Proteins 0.000 description 1
- 101000956094 Homo sapiens Protein Daple Proteins 0.000 description 1
- 101000695187 Homo sapiens Protein patched homolog 1 Proteins 0.000 description 1
- 101001066905 Homo sapiens Pyridoxine-5'-phosphate oxidase Proteins 0.000 description 1
- 101000597542 Homo sapiens Pyruvate dehydrogenase protein X component, mitochondrial Proteins 0.000 description 1
- 101000665449 Homo sapiens RNA binding protein fox-1 homolog 1 Proteins 0.000 description 1
- 101001061919 Homo sapiens Ras-related protein Rab-39B Proteins 0.000 description 1
- 101000641879 Homo sapiens Ras/Rap GTPase-activating protein SynGAP Proteins 0.000 description 1
- 101000579226 Homo sapiens Renin receptor Proteins 0.000 description 1
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 1
- 101000846198 Homo sapiens Ribitol 5-phosphate transferase FKRP Proteins 0.000 description 1
- 101000846336 Homo sapiens Ribitol-5-phosphate transferase FKTN Proteins 0.000 description 1
- 101001103771 Homo sapiens Ribonuclease H2 subunit A Proteins 0.000 description 1
- 101001103768 Homo sapiens Ribonuclease H2 subunit B Proteins 0.000 description 1
- 101000670585 Homo sapiens Ribonuclease H2 subunit C Proteins 0.000 description 1
- 101000654718 Homo sapiens SET-binding protein Proteins 0.000 description 1
- 101000936922 Homo sapiens Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Proteins 0.000 description 1
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 description 1
- 101000987315 Homo sapiens Serine/threonine-protein kinase PAK 3 Proteins 0.000 description 1
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 description 1
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 1
- 101000684813 Homo sapiens Sodium channel subunit beta-1 Proteins 0.000 description 1
- 101000753197 Homo sapiens Sodium/potassium-transporting ATPase subunit alpha-2 Proteins 0.000 description 1
- 101000704203 Homo sapiens Spectrin alpha chain, non-erythrocytic 1 Proteins 0.000 description 1
- 101000881206 Homo sapiens Spermine synthase Proteins 0.000 description 1
- 101000633429 Homo sapiens Structural maintenance of chromosomes protein 1A Proteins 0.000 description 1
- 101000708766 Homo sapiens Structural maintenance of chromosomes protein 3 Proteins 0.000 description 1
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 1
- 101000629629 Homo sapiens Sushi repeat-containing protein SRPX2 Proteins 0.000 description 1
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 description 1
- 101000695522 Homo sapiens Synaptophysin Proteins 0.000 description 1
- 101000648077 Homo sapiens Syntaxin-binding protein 1 Proteins 0.000 description 1
- 101000830956 Homo sapiens Three-prime repair exonuclease 1 Proteins 0.000 description 1
- 101000976959 Homo sapiens Transcription factor 4 Proteins 0.000 description 1
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 description 1
- 101000795659 Homo sapiens Tuberin Proteins 0.000 description 1
- 101000762128 Homo sapiens Tumor suppressor candidate 3 Proteins 0.000 description 1
- 101001033034 Homo sapiens UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Proteins 0.000 description 1
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 description 1
- 101000854879 Homo sapiens V-type proton ATPase 116 kDa subunit a 2 Proteins 0.000 description 1
- 101000667092 Homo sapiens Vacuolar protein sorting-associated protein 13A Proteins 0.000 description 1
- 101000932804 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1H Proteins 0.000 description 1
- 101000739853 Homo sapiens [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920003012 Hydroxypropyl distarch phosphate Polymers 0.000 description 1
- 201000000101 Hyperekplexia Diseases 0.000 description 1
- 206010058271 Hyperexplexia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108010007666 IMP cyclohydrolase Proteins 0.000 description 1
- 102100025141 IQ motif and SEC7 domain-containing protein 2 Human genes 0.000 description 1
- 208000028547 Inborn Urea Cycle disease Diseases 0.000 description 1
- 102100020796 Inosine 5'-monophosphate cyclohydrolase Human genes 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 101150086199 KCNMA1 gene Proteins 0.000 description 1
- 102100025188 KIF-binding protein Human genes 0.000 description 1
- 102100029874 Kappa-casein Human genes 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 206010023388 Ketonuria Diseases 0.000 description 1
- 102100020920 L-2-hydroxyglutarate dehydrogenase, mitochondrial Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100038889 Laforin, isoform 9 Human genes 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 1
- 102100022275 Leucine-rich glioma-inactivated protein 1 Human genes 0.000 description 1
- DBGIVFWFUFKIQN-SECBINFHSA-N Levofenfluramine Chemical compound CCN[C@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-SECBINFHSA-N 0.000 description 1
- 229940110339 Long-acting muscarinic antagonist Drugs 0.000 description 1
- 102100033249 Lysine-specific demethylase 5C Human genes 0.000 description 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108010018650 MEF2 Transcription Factors Proteins 0.000 description 1
- 102100021760 Magnesium transporter protein 1 Human genes 0.000 description 1
- 101150017238 Magt1 gene Proteins 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 description 1
- 102100028328 Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 Human genes 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 244000024873 Mentha crispa Species 0.000 description 1
- 235000014749 Mentha crispa Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102100031551 Methionine synthase Human genes 0.000 description 1
- 102100024614 Methionine synthase reductase Human genes 0.000 description 1
- 102100029684 Methylenetetrahydrofolate reductase Human genes 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102100027891 Mitochondrial chaperone BCS1 Human genes 0.000 description 1
- 102100040273 Mitochondrial glutamate carrier 1 Human genes 0.000 description 1
- 102100035971 Molybdopterin molybdenumtransferase Human genes 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 208000011093 Myoclonus-dystonia syndrome Diseases 0.000 description 1
- 102100039229 Myocyte-specific enhancer factor 2C Human genes 0.000 description 1
- 102100031688 N-acetylgalactosamine-6-sulfatase Human genes 0.000 description 1
- 102100036710 N-acetylglucosamine-1-phosphotransferase subunits alpha/beta Human genes 0.000 description 1
- 102100023282 N-acetylglucosamine-6-sulfatase Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100021582 Neurexin-1-beta Human genes 0.000 description 1
- 102100035585 Neuronal acetylcholine receptor subunit alpha-2 Human genes 0.000 description 1
- 102100039909 Neuronal acetylcholine receptor subunit alpha-4 Human genes 0.000 description 1
- 102100030912 Neuronal acetylcholine receptor subunit beta-2 Human genes 0.000 description 1
- 102100025929 Neuronal migration protein doublecortin Human genes 0.000 description 1
- 102100037591 Neuroserpin Human genes 0.000 description 1
- 101100438536 Nicotiana plumbaginifolia CABC gene Proteins 0.000 description 1
- 102100035377 Nipped-B-like protein Human genes 0.000 description 1
- 102000001760 Notch3 Receptor Human genes 0.000 description 1
- 108010029756 Notch3 Receptor Proteins 0.000 description 1
- 102100023311 Nuclear distribution protein nudE homolog 1 Human genes 0.000 description 1
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 description 1
- 102100035592 Oligophrenin-1 Human genes 0.000 description 1
- 102100025410 Oral-facial-digital syndrome 1 protein Human genes 0.000 description 1
- 101100448729 Oryza sativa subsp. japonica GLB gene Proteins 0.000 description 1
- 102100026365 PHD finger protein 6 Human genes 0.000 description 1
- 101710125553 PLA2G6 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100035196 POLG alternative reading frame Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 102100024127 Pantothenate kinase 2, mitochondrial Human genes 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 102100024315 Pericentrin Human genes 0.000 description 1
- 102100026798 Peroxisomal acyl-coenzyme A oxidase 1 Human genes 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 102100035985 Phosphatidylinositol 4,5-bisphosphate 5-phosphatase A Human genes 0.000 description 1
- 102100040748 Polyglutamine-binding protein 1 Human genes 0.000 description 1
- 206010036312 Post-traumatic epilepsy Diseases 0.000 description 1
- 102100033508 Potassium channel subfamily T member 1 Human genes 0.000 description 1
- 102100034368 Potassium voltage-gated channel subfamily A member 1 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710119292 Probable D-lactate dehydrogenase, mitochondrial Proteins 0.000 description 1
- 102100028840 Proline-rich transmembrane protein 2 Human genes 0.000 description 1
- 102100038589 Protein Daple Human genes 0.000 description 1
- 102100028680 Protein patched homolog 1 Human genes 0.000 description 1
- 102100034407 Pyridoxine-5'-phosphate oxidase Human genes 0.000 description 1
- 108010042687 Pyruvate Oxidase Proteins 0.000 description 1
- 102100035459 Pyruvate dehydrogenase protein X component, mitochondrial Human genes 0.000 description 1
- 102100038188 RNA binding protein fox-1 homolog 1 Human genes 0.000 description 1
- 102000011070 Rab3 Human genes 0.000 description 1
- 102100029547 Ras-related protein Rab-39B Human genes 0.000 description 1
- 102100033428 Ras/Rap GTPase-activating protein SynGAP Human genes 0.000 description 1
- 102000043322 Reelin Human genes 0.000 description 1
- 108700038365 Reelin Proteins 0.000 description 1
- 101150057388 Reln gene Proteins 0.000 description 1
- 102100028254 Renin receptor Human genes 0.000 description 1
- 101001030849 Rhinella marina Mesotocin receptor Proteins 0.000 description 1
- 102100031774 Ribitol 5-phosphate transferase FKRP Human genes 0.000 description 1
- 102100031754 Ribitol-5-phosphate transferase FKTN Human genes 0.000 description 1
- 102100039493 Ribonuclease H2 subunit A Human genes 0.000 description 1
- 102100039474 Ribonuclease H2 subunit B Human genes 0.000 description 1
- 102100039610 Ribonuclease H2 subunit C Human genes 0.000 description 1
- 108700019718 SAM Domain and HD Domain-Containing Protein 1 Proteins 0.000 description 1
- 101150114242 SAMHD1 gene Proteins 0.000 description 1
- 102100032741 SET-binding protein Human genes 0.000 description 1
- 108091006162 SLC17A6 Proteins 0.000 description 1
- 102000012977 SLC1A3 Human genes 0.000 description 1
- 108091006426 SLC25A22 Proteins 0.000 description 1
- 108091006296 SLC2A1 Proteins 0.000 description 1
- 108091006265 SLC4A10 Proteins 0.000 description 1
- 108091006657 SLC9A6 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 101000930003 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Diacylglycerol O-acyltransferase 1 Proteins 0.000 description 1
- 101000744436 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) Trans-acting factor D Proteins 0.000 description 1
- 102100027732 Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 Human genes 0.000 description 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 description 1
- 102100027911 Serine/threonine-protein kinase PAK 3 Human genes 0.000 description 1
- 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 1
- 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102100027195 Sodium channel protein type 4 subunit alpha Human genes 0.000 description 1
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 1
- 102100023732 Sodium channel subunit beta-1 Human genes 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 102000006633 Sodium-Bicarbonate Symporters Human genes 0.000 description 1
- 102100029972 Sodium/hydrogen exchanger 6 Human genes 0.000 description 1
- 102100021955 Sodium/potassium-transporting ATPase subunit alpha-2 Human genes 0.000 description 1
- 102100023536 Solute carrier family 2, facilitated glucose transporter member 1 Human genes 0.000 description 1
- 102100031874 Spectrin alpha chain, non-erythrocytic 1 Human genes 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 102100029538 Structural maintenance of chromosomes protein 1A Human genes 0.000 description 1
- 102100032723 Structural maintenance of chromosomes protein 3 Human genes 0.000 description 1
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102100026826 Sushi repeat-containing protein SRPX2 Human genes 0.000 description 1
- 102100021905 Synapsin-1 Human genes 0.000 description 1
- 102100028706 Synaptophysin Human genes 0.000 description 1
- 102100025293 Syntaxin-binding protein 1 Human genes 0.000 description 1
- 101100219120 Theobroma cacao BTS1 gene Proteins 0.000 description 1
- 102100024855 Three-prime repair exonuclease 1 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102100023489 Transcription factor 4 Human genes 0.000 description 1
- 102100031638 Tuberin Human genes 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 102100024248 Tumor suppressor candidate 3 Human genes 0.000 description 1
- 102100038413 UDP-N-acetylglucosamine-dolichyl-phosphate N-acetylglucosaminephosphotransferase Human genes 0.000 description 1
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 description 1
- 206010057362 Underdose Diseases 0.000 description 1
- 102100020745 V-type proton ATPase 116 kDa subunit a 2 Human genes 0.000 description 1
- 101150084765 VPS gene Proteins 0.000 description 1
- 102100039114 Vacuolar protein sorting-associated protein 13A Human genes 0.000 description 1
- 102000046053 Vesicular Glutamate Transport Protein 2 Human genes 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 102000056014 X-linked Nuclear Human genes 0.000 description 1
- 108700042462 X-linked Nuclear Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- 102100025093 Zinc fingers and homeoboxes protein 2 Human genes 0.000 description 1
- ZPCCSZFPOXBNDL-ZSTSFXQOSA-N [(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2r,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-5-methoxy-9,16-dimethyl-2-oxo-7-(2-oxoe Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@H]([C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)OC(C)=O)[C@H]1CC[C@H](N(C)C)[C@@H](C)O1 ZPCCSZFPOXBNDL-ZSTSFXQOSA-N 0.000 description 1
- 102100037607 [3-methyl-2-oxobutanoate dehydrogenase [lipoamide]] kinase, mitochondrial Human genes 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000011374 additional therapy Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 208000029650 alcohol withdrawal Diseases 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 208000022877 amino acid metabolic disease Diseases 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000573 anti-seizure effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000019312 arabinogalactan Nutrition 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000008233 autosomal dominant nocturnal frontal lobe epilepsy Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 201000008916 benign epilepsy with centrotemporal spikes Diseases 0.000 description 1
- 201000008181 benign familial infantile epilepsy Diseases 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000008436 biogenesis Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000008236 biological pathway Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019428 bleached starch Nutrition 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 229940095618 calcium glycerophosphate Drugs 0.000 description 1
- UHHRFSOMMCWGSO-UHFFFAOYSA-L calcium glycerophosphate Chemical compound [Ca+2].OCC(CO)OP([O-])([O-])=O UHHRFSOMMCWGSO-UHFFFAOYSA-L 0.000 description 1
- 235000019299 calcium glycerylphosphate Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229940095643 calcium hydroxide Drugs 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 208000026099 carbohydrate metabolic disease Diseases 0.000 description 1
- 230000009787 cardiac fibrosis Effects 0.000 description 1
- 208000015278 cerebellar malformation Diseases 0.000 description 1
- 208000017888 childhood-onset epilepsy syndrome Diseases 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 208000015134 congenital hypothalamic hamartoma syndrome Diseases 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000005536 corrosion prevention Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000020805 dietary restrictions Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical class OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 201000008028 electroclinical syndrome Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 201000002933 epilepsy with generalized tonic-clonic seizures Diseases 0.000 description 1
- 208000028329 epileptic seizure Diseases 0.000 description 1
- 230000002397 epileptogenic effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229960001003 etilamfetamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical class C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 1
- 201000007186 focal epilepsy Diseases 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 229960000693 fosphenytoin Drugs 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000005891 glutamate uptake involved in synaptic transmission Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 208000011316 hemodynamic instability Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000013825 hydroxy propyl distarch phosphate Nutrition 0.000 description 1
- 239000001310 hydroxy propyl distarch phosphate Substances 0.000 description 1
- DVROLKBAWTYHHD-UHFFFAOYSA-N hydroxy propyl distarch phosphate Chemical compound OC1C(O)C(OC)OC(CO)C1OC(O)CCOC1C(OC2C(C(O)C(OC3C(C(OP(O)(=O)OC4C(C(O)C(OC)OC4CO)O)C(C)OC3CO)O)OC2COC2C(C(O)C(OC)C(CO)O2)O)O)OC(CO)C(OC)C1O DVROLKBAWTYHHD-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009539 inhibitory neurotransmission Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000013021 intended final formulation Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000000905 isomalt Substances 0.000 description 1
- 235000010439 isomalt Nutrition 0.000 description 1
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000020855 low-carbohydrate diet Nutrition 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960001708 magnesium carbonate Drugs 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000001755 magnesium gluconate Substances 0.000 description 1
- 235000015778 magnesium gluconate Nutrition 0.000 description 1
- 229960003035 magnesium gluconate Drugs 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- OVGXLJDWSLQDRT-UHFFFAOYSA-L magnesium lactate Chemical compound [Mg+2].CC(O)C([O-])=O.CC(O)C([O-])=O OVGXLJDWSLQDRT-UHFFFAOYSA-L 0.000 description 1
- 239000000626 magnesium lactate Substances 0.000 description 1
- 235000015229 magnesium lactate Nutrition 0.000 description 1
- 229960004658 magnesium lactate Drugs 0.000 description 1
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 229960002366 magnesium silicate Drugs 0.000 description 1
- IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 235000002648 merrit Nutrition 0.000 description 1
- 244000087976 merrit Species 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229940029985 mineral supplement Drugs 0.000 description 1
- 235000020786 mineral supplement Nutrition 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000003346 myoclonic dystonia Diseases 0.000 description 1
- 230000002151 myoclonic effect Effects 0.000 description 1
- 208000013522 myoclonic encephalopathy in non-progressive disease Diseases 0.000 description 1
- 239000004081 narcotic agent Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000022145 neurocutaneous syndrome Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000008587 neuronal excitability Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000010525 oxidative degradation reaction Methods 0.000 description 1
- 235000013808 oxidized starch Nutrition 0.000 description 1
- 239000001254 oxidized starch Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 238000011349 peptide receptor radionuclide therapy Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 208000023269 peroxisome biogenesis disease Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- 229960000247 phenylmercuric borate Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 101150098238 pont gene Proteins 0.000 description 1
- 208000004351 pontocerebellar hypoplasia Diseases 0.000 description 1
- 150000004032 porphyrins Chemical class 0.000 description 1
- 229940126027 positive allosteric modulator Drugs 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 229940099402 potassium metaphosphate Drugs 0.000 description 1
- 235000019828 potassium polyphosphate Nutrition 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 201000001729 primary autosomal recessive microcephaly Diseases 0.000 description 1
- 239000000640 processed eucheuma seaweed Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- IBALRBWGSVJPAP-HEHNFIMWSA-N progabide Chemical compound C=1C(F)=CC=C(O)C=1C(=N/CCCC(=O)N)/C1=CC=C(Cl)C=C1 IBALRBWGSVJPAP-HEHNFIMWSA-N 0.000 description 1
- 229960002752 progabide Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- DPBVJRXPSXTHOL-UHFFFAOYSA-N propyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCCC DPBVJRXPSXTHOL-UHFFFAOYSA-N 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 229960000957 prothipendyl Drugs 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- FBNCDBZHLBYPGY-UHFFFAOYSA-N pyridine;dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=[NH+]C=C1.C1=CC=[NH+]C=C1 FBNCDBZHLBYPGY-UHFFFAOYSA-N 0.000 description 1
- 108010065559 rab3 GTP-Binding Proteins Proteins 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000011833 salt mixture Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- WSWCOQWTEOXDQX-MQQKCMAXSA-N sorbic acid group Chemical group C(\C=C\C=C\C)(=O)O WSWCOQWTEOXDQX-MQQKCMAXSA-N 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000019614 sour taste Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 235000013826 starch sodium octenyl succinate Nutrition 0.000 description 1
- 239000001334 starch sodium octenyl succinate Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012496 stress study Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960004016 sucrose syrup Drugs 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- WWJZWCUNLNYYAU-UHFFFAOYSA-N temephos Chemical compound C1=CC(OP(=S)(OC)OC)=CC=C1SC1=CC=C(OP(=S)(OC)OC)C=C1 WWJZWCUNLNYYAU-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 208000030954 urea cycle disease Diseases 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/332—Promoters of weight control and weight loss
- A23V2200/3322—Low carb - reduced carbohydrate content
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
一种治疗被诊断患有癫痫亚型的患者的癫痫亚型、例如德拉韦综合征的症状的方法,所述方法通过在足以降低或完全消除患者的癫痫发作的时间段内,将有效剂量的芬氟拉明制剂与生酮饮食组合给药于所述患者。还提供了可用于实施所述方法的实施方案的组合物和试剂盒。
Description
技术领域
描述了一种治疗患有癫痫亚型(例如,德拉韦(Dravet)综合征、伦诺克斯-加斯托(Lennox-Gastaut)综合征、多泽(Doose)综合征)的患者的方法,借此用芬氟拉明制剂(fenfluramine formulation)组合生酮饮食(ketogenic diet)来治疗该患者。
背景技术
本发明涉及使用苯丙胺(amphetamine)衍生物、特别是芬氟拉明治对癫痫亚型(例如,德拉韦综合征、伦诺克斯-加斯托综合征、多泽综合征)的治疗。
芬氟拉明,即3-三氟甲基-N-乙基苯丙胺,是一种苯丙胺衍生物,其具有以下结构:
结构1
(RS)-N-乙基-1-[3-(三氟甲基)苯基]丙烷-2-胺
芬氟拉明于1973年首次在美国销售,并且已经与苯丁胺组合给药以预防和治疗肥胖症。然而,在1997年,芬氟拉明从美国市场撤出,因为其使用与心脏瓣膜纤维化(cardiacfibrosis)和肺动脉高血压(pulmonary hypertension)的发病相关联。随后,该药物在全球性销售中撤出,并且不再被指示用于任何治疗领域。
尽管围绕芬氟拉明存在健康问题,但已做出了尝试以鉴定该产品的进一步治疗用途。艾卡尔迪(Aicardi)和加斯托(Gastaut)(新英格拉医学杂志(New England Journal ofMedicine)(1985),313:1419和神经病学档案(Archives ofNeurology)(1988)45:923-925)报道了四例对芬氟拉明治疗有反应的自诱发光敏性癫痫发作(self-inducedphotosensitive seizure)。
克莱门斯(Clemens)在癫痫研究(Epilepsy Research)(1988)2:340-343中报道了关于患有模式敏感性诱发癫痫发作(pattern sensitivity-induced seizures)的男孩的研究,这类模式敏感性诱发癫痫发作对抗惊厥(anticonvulsive)治疗有抵抗力。据报道,芬氟拉明成功地终止了这些自诱发的癫痫发作,并且作者推断这是因为芬氟拉明阻断了光敏引发机制。
在神经儿科(Neuropaediatrics),(1996);27(4):171-173中,博埃尔(Boel)和卡瑟尔(Casaer)报道了关于芬氟拉明对患有难治性癫痫(refractory epilepsy)的儿童的作用研究。他们推断,当芬氟拉明以0.5至1mg/kg/天的剂量给药时,这导致患者所经历的癫痫发作(seizure)的次数减少。
在该期刊发表的给癫痫杂质(Epilepsia)的一封信中(Epilepsia,43(2):205-206,2002),博埃尔和卡瑟尔评论了芬氟拉明似乎在患有顽固性癫痫(intractableepilespsy)的患者中具有治疗益处。
癫痫(epilepsy)是以对反复癫痫发作的易感性为特征的大脑病症。存在很多癫痫的病因,包括但不限于出生创伤、围产期感染、缺氧、传染病、毒素摄入、脑瘤、遗传性障碍或退行性障碍、头部损伤或创伤、代谢障碍、脑血管意外、和酒精戒断。
存在大量已经表征的癫痫亚型。例如,国际抗癫痫联盟(“ILAE”)分类和术语委员会采用的最新分类系统提供了以下癫痫综合征列表(参见伯格(Berg)等,“癫痫发作组织的修订术语和概念”,Epilepsia,51(4):676-685(2010)):
I.按发病年龄排列的电临床综合征(electroclinical syndromes)
A.新生儿期(1.良性家族性新生儿癫痫(benign familial neonatal epilepsy,BFNE),2.早期肌阵挛性脑病(early myoclonic encephalopathy,EME),3.大田原(Ohtahara)综合征),
B.婴儿期(1.伴游走性局灶性癫痫发作婴儿癫痫,2.韦斯特(West)综合征,3.婴儿肌阵挛性癫痫(MEI),4.良性婴儿癫痫,5.良性家族性婴儿癫痫,6.德拉韦综合征,7.非进行性障碍中的肌阵挛性脑病),
C.儿童期(1.热性惊厥附加症(febrile seizures plus)(FS+)(可在婴儿期发病),2.帕纳约托普洛斯(Panayiotopoulos)综合征,3.癫痫伴肌阵挛性失张力(先前为站立不能(previously astatic))癫痫发作(多泽综合征),4.伴中央颞区棘波的良性癫痫(benign epilepsy with centrotemporal spikes,BECTS),5.常染色体显性夜发性额叶癫痫(autosomal-dominant nocturnal frontal lobe epilepsy,ADNFLE),6.晚发型儿童枕叶癫痫(加斯托型),7.伴肌阵挛性失神性癫痫,8.伦诺克斯-加斯托综合征,9.伴睡眠期持续棘慢复合波的癫痫性脑病(epileptic encephalopathy with continuous spike-and-wave during sleep),10.兰道(Landau)-克莱夫纳(Kleffner)综合征(LKS),11.儿童失神性癫痫(CAE));
D.青春期-成年期(1.少年失神性癫痫(JAE),2.少年肌阵挛性癫痫(JME),3.单纯癫痫伴全身性强直-阵挛性癫痫发作,4.进行性肌阵挛性癫痫(PME),5.伴听觉特征的常染色体显性癫痫(ADEAF),6.其他家族性颞叶癫痫,
E.较少特定年龄关系(1.家族性局灶性癫痫伴可变病灶(familial focalepilepsy with variable foci)(儿童期至成年期),2.反射性癫痫);
II.特殊群体(distinctive constellations):A.伴海马硬化的内侧颞叶癫痫(伴HS的MTLE),B.拉斯马森(Rasmussen)综合征,C.伴下丘脑错构瘤的痴笑性癫痫发作(gelastic seizures with hypothalamic hamartoma),D.偏侧惊厥-偏瘫-癫痫(hemiconvulsion-hemiplegia-epilepsy),E.其他癫痫,是通过1.推测的病因(存在或不存在已知的结构性或代谢性病症)、然后2.癫痫发作发病的主要模式(全身性的与局灶性的)而区别的;
III.归因于结构性-代谢性病因以及由其组织的癫痫:A.皮质发育畸形(半侧巨脑症(hemimegalencephaly)、异位等),B.神经皮肤综合征(结节性硬化症、斯特奇(Sturge)-韦伯(Weber)等),C.肿瘤,D.感染,E.创伤;
IV.血管瘤:A.围产期损伤,B.中风,C.其他病因;
V.病因不明的癫痫;
VI.传统上本身不诊断为癫痫形式的伴癫痫性发作的病症;A.良性新生儿癫痫发作(BNS);和B.热性惊厥(FS)。
参见伯格等,“癫痫发作组织的修订术语和概念,”Epilepsia,51(4):676-685(2010)。
例如,从该列表的第五(V)部分可以看出,仍有尚未完全表征的癫痫亚型,因此,该列表还远远不够完整。
本领域技术人员将认识到,这些癫痫亚型由不同的刺激引发,由不同的生物学途径控制,并具有不同的病因,无论是遗传性的还是环境性的。换言之,技术人员将认识到,与一种癫痫亚型有关的教导不一定适于其他亚型。这可以包括不同的癫痫亚型对不同的抗惊厥药物不同反应的认识。
德拉韦综合征是始于婴儿期的罕见且灾难性形式的顽固性癫痫。最初,患者会经历长期的癫痫发作。在他们第二年中,可能由于反复的脑缺氧,其他类型的癫痫发作开始出现,这通常与发育下降同时发生。这导致语言和运动技能的发展不佳。
患有德拉韦综合征的儿童每天可能会经历多次癫痫发作。癫痫发作更可能导致德拉韦综合征患者的死亡;约有10至15%的诊断为患有德拉韦综合征的患者在儿童期死亡,尤其是在两岁至四岁之间。另外,患者处于多种相关联病症的风险中,包括骨发育问题、生长受损和慢性感染。
特别要注意的是,患有德拉韦综合征的儿童特别容易受到癫痫持续状态的发作(episode)的影响。这种严重且难治的病症被归类为需要立即进行医疗干预的医疗紧急事件,通常涉及住院治疗。癫痫持续状态可以是致命的。它还可能与脑缺氧相关联,可能导致对脑组织的损伤。患有德拉韦综合征的儿童的频繁住院显然是很痛苦的,不仅对患者而且对家庭和看护者也是如此。生酮饮食与包括难治性癫痫持续状态的癫痫持续状态的发生和严重程度的降低相关联,并被用作第二线辅助治疗或第三线辅助治疗(威廉姆斯(Williams),T.等.临床神经生理学实践,第2卷,第154-160页(2017))。
对患有癫痫、诸如德拉韦综合征的患者的护理费用也很高,因为受影响的儿童需要持续的监管,并且许多影响的儿童在他们到了十几岁时就需要机构化(institutionalization)。
目前,尽管许多抗惊厥疗法可以用于减少患有德拉韦综合征的患者的癫痫发作的实例,但是用这些疗法获得的结果通常较差,并且那些疗法最多只能影响癫痫发作的部分停止(cessation)。与德拉韦综合征相关的癫痫发作通常对常规治疗具有耐药性(resistant)。此外,许多抗惊厥药,诸如氯巴占(clobazam)和氯硝西泮(clonazepam)具有不良的副作用,这在小儿患者中尤其严重。
司替戊醇(Stiripentol)在欧洲、加拿大和澳大利亚获得了批准,并且最近才被获准在美国销售,用于德拉韦综合征的治疗。尽管司替戊醇本身作为GABAA受体调节剂具有一些抗惊厥活性,但是它主要是通过抑制其他抗惊厥药的代谢,从而延长其活性来起作用。它被标记为连同氯巴占和丙戊酸盐(valproate)一起使用。然而,由于其对肝细胞色素P450酶的抑制作用,因此关于司替戊醇的使用仍然存在担忧。此外,司替戊醇与大量药物的相互作用意味着组合疗法(这是患有德拉韦综合征的患者通常需要的)是有问题的。另外,司替戊醇的有效性是有限的,几乎没有患者可以无癫痫发作。
用于治疗德拉韦综合征的、使用两种以上抗癫痫药物的多药疗法(polytherapy)可能会导致显著的患者负担,因为可能会积累来自多种药物的副作用或不良事件,并导致限制了疗法的功效。
德拉韦综合征的非药理学治疗(non-pharmacological treatment)已经包括了调节患者饮食。1921年,利用生酮饮食来诱导禁食的代谢作用,用于癫痫发作的管理(怀尔德(Wilder)等.生酮血症(ketogenemia)对癫痫病程(course)的影响.Mayo Clin.Bull.,1921年,2:307–14)。随着抗癫痫药物的使用的增长,该饮食被保留,以供在选定患者中使用。然而,近几十年来,治疗中心一直在采用经典的生酮饮食。该饮食由摄入碳水化合物和蛋白质结合的三到四倍的脂肪组成。
生酮饮食现已成为用于管理顽固性癫痫的已证实的(established)替代选择。在卡拉巴洛(Caraballo)等人的研究中,例如,向患有伦诺克斯-加斯托综合征(LGS)的受试者(subject)给药该饮食,该伦诺克斯-加斯托综合征(LGS)以高癫痫发作频率和对抗癫痫药物的耐药性(refractoriness)为特征。进行该饮食18个月后,进行该饮食的40%的患者实现了超过50%的癫痫发作减少。研究得出结论,生酮饮食、尤其是约翰霍普金斯(JohnsHopkins)方案,对患有LGS的患者是有效且耐受良好的选择(卡拉巴洛等.患有伦诺克斯-加斯托综合征的患者的生酮饮食.癫痫发作(seizure),2014,23(9):751-5)。
进行生酮饮食的患者通常具有宽范围的碳水化合物热量摄入,并且可能还在服用几种药物。液体药物通常含有调味剂和甜味剂(flavoring and sweetening agent),这些调味剂和甜味剂每天向患者的饮食中添加几克碳水化合物。然而,该饮食的成功取决于对碳水化合物的限制,以促进酮症(ketosis),酮症是血液中的酮体提供能量的代谢状态。无法监测药物的碳水化合物含热量可能会破坏该饮食。
因此,需要提供一种改进的方法,该方法用于治疗或预防癫痫(例如,德拉韦综合征、伦诺克斯-加斯托综合征、多泽综合征)和/或用于治疗、预防和/或减轻进行生酮饮食的具有癫痫亚型的患者经历的癫痫发作。
发明内容
本发明是一种在诊断患有癫痫亚型(例如,德拉韦综合征、伦诺克斯-加斯托综合征和多泽综合征)的患者中增加对生酮饮食的依从性的方法,其中所述癫痫对先前的治疗方案是难治性的,所述方法包括向受试者给药治疗有效剂量的芬氟拉明制剂,该芬氟拉明制剂缺乏营养性(nutritive)/可消化性(digestible)/血糖性(glycemic)碳水化合物,其中所述制剂减少了患者对碳水化合物的渴望。
在某些方面,本文描述了治疗开始或维持生酮饮食方案的、患有德拉韦综合征、伦诺克斯-加斯托综合征或多泽综合征的患者的方法,所述方法包括向所述患者给药不含可消化性碳水化合物的芬氟拉明制剂,并且所述给药降低所述患者对碳水化合物的渴望,从而促成(facilitate)/促进(promote)对所述生酮饮食的坚持。
在本发明的一方面中,制剂制成使得该制剂与患有癫痫亚型的受试者的生酮饮食相容,该癫痫亚型诸如德拉韦综合征、伦诺克斯-加斯托综合征或多泽综合征的。在本发明的一方面中,芬氟拉明制剂的给药在患有德拉韦综合征或其他难治性癫痫的患者中改进了对生酮饮食的依从性。
在另一方面,本文描述了用于治疗癫痫的液体芬氟拉明制剂,其中所述制剂不含可消化性碳水化合物,并且所述制剂降低碳水化合物的渴望,从而促进对生酮饮食的坚持。
还提供了在实施所述方法的实施方案使用的组合物和试剂盒。
具体实施方式
在描述本治疗方法之前,应当理解,本发明不限于所描述的特定方法,正因如此,本发明当然可以变化。也应理解,本文中使用的术语仅是为了描述特定实施方案的目的,而不旨在是限制性的,因为本发明的范围将仅受所附权利要求的限制。
在提供一系列值的情况下,应当理解,除非上下文另有明确规定,否则还具体公开了范围的上限和下限之间的各中间值,直至该下限的单位的十分之一。在规定范围中的任何规定值或中间值和该规定范围中的任何其他规定或中间值之间的各较小范围都包含在本发明内。这些较小范围的上限和下限可以独立地包括或排除在该范围内,且上下限的任一者、两者都不或两者都包括在这些较小范围中的各范围也包含在本发明内,受制于所述范围中的任何具体排除的限制。在规定范围包括一个或两个限制的情况下,排除那些包括的限制之一或两者的范围也包括在本发明中。
除非另外定义,否则本文使用的所有技术和科学术语具有与本发明所属领域的普通技术人员通常理解的含义相同的含义。尽管与本文描述的方法和材料类似或等同的任何方法和材料可用于本发明的实践或测试,但现在描述了一些潜在和优选的方法和材料。本文提及的所有出版物均通过引用并入本文,以公开和描述与所引用的出版物相关的方法和/或材料。应当理解,本公开在有矛盾的程度下取代所结合的出版物的任何公开内容。
必须注意的是,如本文和所附权利要求中所使用的,除非上下文另有明确说明,否则单数形式“一(a)”、“一个(an)”和“该(the)”包括复数指示物。因此,例如,提及“给药步骤”包括多个这样的步骤,而提及“症状”包括提及一种或多种症状及其本领域技术人员已知的等同物,等等。
本文中讨论的出版物仅为了它们的、在本申请的递交日之前的公开而提供。本文中的任何内容均不应被解释为承认本发明无权由于在先发明而先于这些出版物。另外,提供的出版物的日期可能与实际出版日期不同,实际出版日期可能需要单独地确认。
本发明的具体方面
多年的广泛研究之后,意外地发现了芬氟拉明可以如本文所描述地给药,以降低或消除患有德拉韦综合征、伦诺克斯-加斯托综合征或多泽综合征的患者的癫痫发作。例如,在库勒曼(Ceulemans)等.Epilepsia(2012)53(7):1131-1139的文章中确认了这一点,改文章的内容合并于此。
为了避免疑问,术语癫痫发作的“预防”是指癫痫发作的完全或部分预防(抑制)。理想地,本发明的方法导致癫痫发作的完全预防;实际上,在由发明人治疗的许多患者中已经实现了这一理想。然而,本发明还涵盖将癫痫发作的实例减少至少50%、至少60%、至少70%、至少80%或至少90%的方法。
已知患有德拉韦综合征的患者通常会经历光敏性癫痫发作或诱发性癫痫发作。来自现有技术的教导,例如上面讨论的两项-艾卡尔迪和加斯托(1988)以及博埃尔和卡瑟尔(1996)-可以预期,芬氟拉明会降低光敏性癫痫发作或诱发性癫痫发作。然而,在一些实例中,令人惊讶地发现,患有德拉韦综合征的患者表现出的所有类型的癫痫发作、即除光敏性或诱发性的癫痫发作之外或不同于光敏性或诱发性的癫痫发作的癫痫发作,可以通过根据本发明的方法的治疗来抑制。因此,在本发明的上下文中,术语“癫痫发作”不仅用于涵盖光敏性癫痫发作或诱发性癫痫发作,而且还涵盖患有癫痫的患者所经历的一些或全部其他类型的癫痫发作。
存在许多可表明癫痫亚型和/或有关综合征的基因突变,癫痫亚型和/或有关综合征例如德拉韦综合征、伦诺克斯-加斯托综合征、多泽综合征和韦斯特综合征,所有这些以难治性癫痫(难以治疗或管理)为特征。
已经表征了大量癫痫亚型。例如,梅里特的神经病学(Meritt's Neurology)(第12版)中列出了以下病症列表:I.特发性癫痫综合征(局灶性的或全身性的),A.良性新生儿惊厥,1.家族性,2.非家族性;B.良性儿童癫痫,1.伴中央-中颞棘波(with central-midtemporal spikes),2.伴枕骨棘波;C.儿童/少年失神性癫痫;D.少年肌阵挛性癫痫(包括觉醒(awakening)时的全身性强直-阵挛性癫痫发作);E.特发性癫痫,其他方面(otherwise)未明确。II.症状性癫痫综合征(局灶性的或全身性的),A.韦斯特综合征(婴儿痉挛);B.伦诺克斯-加斯托综合征;C.早期肌阵挛性脑病;D.持续性部分性癫痫(Epilepsiapartialis continua),1.拉斯马森(Rasmussen)综合征(脑炎(encephalitic)形式),2.受限形式;E.获得性癫痫性失语(兰朵-克莱夫纳(Landau-Kleffner)综合征);F.颞叶癫痫;G.额叶癫痫;H.创伤后癫痫;I.其他未明确的局灶性或全身性的症状性癫痫。III.其他不确定或混合分类的癫痫综合征,A.新生儿癫痫发作,B.热性惊厥,C.反射性癫痫,D.。
在一个方面,本文提供了一种在患有难治性癫痫的患者中增加对生酮饮食的依从性的方法,所述方法包括给药芬氟拉明制剂,该芬氟拉明制剂缺乏营养性/可消化性/血糖性碳水化合物,其中所述制剂减少了患者对碳水化合物的渴望。
在某些方面,本文提供了治疗开始或维持生酮饮食方案的、患有德拉韦综合征、伦诺克斯-加斯托综合征或多泽综合征的患者的方法,该方法包括向患者给药芬氟拉明制剂,其中,该制剂不含可消化性碳水化合物,并且给药降低患者对碳水化合物的渴望,从而促成/促进对生酮饮食的坚持。
在另一方面,本文提供了用于治疗癫痫的液体芬氟拉明制剂,该制剂不含可消化性碳水化合物,并且该制剂降低碳水化合物的渴望,从而促进对生酮饮食的坚持。
根据本发明的又一方面,本文提供了一种如下所述通过将有效剂量的芬氟拉明与生酮饮食向患者组合给药,来治疗表现出一个、一些或所有基因突变的患者的方法。突变可以包括部分或全部缺失突变、截短(truncating)突变和/或错义(missense)突变。在一些实施方案中,患者已经被诊断患有选自由德拉韦综合征、伦诺克斯-加斯托综合征和多泽综合征组成的组的癫痫亚型。在本发明的该方面的某些实施方案中,患者已经被诊断患有德拉韦综合征。
在一些实例中,突变发生在与以各种癫痫发作类型为特征的疾病和病症关联(linked)的基因中,该癫痫发作类型包括例如全身性癫痫发作、肌阵挛性癫痫发作、失神性癫痫发作和热性惊厥。突变可能发生在以下基因的一个或多个中:ALDH7A1、CACNA1A、CACNA1H、CACNB4、CASR、CHD2、CHRNA2、CHRNA4、CHRNB2、CLCN2、CNTN2、CSTB、DEPDC5、EFHC1、EPM2A、GABRA1、GABRB3、GABRD、GABRG2、GOSR2、GPR98、GRIN1、GRIN2A、GRIN2B、KCNMA1、KCNQ2、KCNQ3、KCTD7、MBD5、ME2、NHLRC1、PCDH19、PRICKLE1、PRICKLE2、PRRT2、SCARB2、SCN1A、SCN1B、SCN2A、SCN4A、SCN9A、SLC2A1、TBC1D24。
在一些实例中,突变发生在与年龄有关癫痫性脑病关联的基因中,该年龄有关癫痫性脑病包括例如早期婴儿癫痫性脑病。突变可能发生在以下基因中的一个或多个中:ALDH7A1、ARHGEF9、ARX、CDKL5、CNTNAP2、FH、FOXG1、GABRG2、GRIN2A、GRIN2B、KCNT1、MAGI2、MAPK10、MECP2、NRXN1、PCDH19、PLCB1、PNKP、PNPO、PRRT2、RNASEH2A、RNASEH2B、RNASEH2C、SAMHD1、SCN1A、SCN1B、SCN2A、SCN8A、SCN9A、SLC25A22、SLC2A1、SLC9A6、SPTAN1、STXBP1、TCF4、TREX1、UBE3A、ZEB2。
在一些实例中,突变发生在与畸形障碍关联的基因中,畸形障碍包括例如神经元迁移障碍、严重的头小畸形(microcephaly)、脑桥小脑发育不全(pontocerebellarhypoplasia)、朱伯特(Joubert)综合征和有关障碍、前脑无裂畸形(holoprosencephaly)以及RAS/MAPK途径的障碍。突变可能发生在以下基因中的一个或多个中:AHI1、ARFGEF2、ARL13B、ARX、ASPM、ATR、BRAF、C12orf57、CASK、CBL、CC2D2A、CDK5RAP2、CDON、CENPJ、CEP152、CEP290、COL18A1、COL4A1、CPT2、DCX、EMX2、EOMES、FGF8、FGFR3、FKRP、FKTN、FLNA、GLI2、GLI3、GPR56、HRAS、INPP5E、KAT6B、KRAS、LAMA2、LARGE、MAP2K1、MAP2K2、MCPH1、MED17、NF1、NPHP1、NRAS、OFD1、PAFAH1B1、PAX6、PCNT、PEX7、PNKP、POMGNT1、POMT1、POMT2、PQBP1、PTCH1、PTPN11、RAB3GAP1、RAF1、RARS2、RELN、RPGRIP1L、SHH、SHOC2、SIX3、SLC25A19、SNAP29、SOS1、SPRED1、SRD5A3、SRPX2、STIL、TGIF1、TMEM216、TMEM67、TSEN2、TSEN34、TSEN54、TUBA1A、TUBA8、TUBB2B、VDAC1、WDR62、VRK1、ZIC2。
在一些实例中,突变发生在与X连锁智力残疾(X-linked intellectualdisability)中的癫痫关联的基因中。突变可能发生在以下基因中的一个或多个中:ARHGEF9、ARX、ATP6AP2、ATP7A、ATRX、CASK、CDKL5、CUL4B、DCX、FGD1、GPC3、GRIA3、HSD17B10、IQSEC2、KDM5C、MAGT1、MECP2、OFD1、OPHN1、PAK3、PCDH19、PHF6、PLP1、PQBP1、RAB39B、SLC16A2、SLC9A6、SMC1A、SMS、SRPX2、SYN1、SYP。
在一些实例中,突变发生在与以细胞器(organelle)功能紊乱为特征的贮积疾病(storage disease)和病症关联的基因中,贮积疾病和病症包括例如神经元蜡样脂褐质沉积症(neuronal ceroid lipofuscinosis)、溶酶体贮积障碍(lysosomal storagedisorders)、先天性糖基化障碍(congenital disorders of glycosylation)、过氧化物酶体生物发生障碍(disorders of peroxisome biogenesis)和脑白质营养不良(leukodystrophies)。突变可能发生在以下基因中的一个或多个中:AGA、ALG1、ALG12、ALG2、ALG3、ALG6、ALG8、ALG9、ALG11、ALG13、ARSA、ARSB、ASPA、B4GALT1、CLN3、CLN5、CLN6、CLN8、COG1、COG4、COG5、COG6、COG7、COG8、CTSA、CTSD、DDOST、DOLK、DPAGT1、DPM1、DPM3、EIF2B1、EIF2B2、EIF2B3、EIF2B4、EIF2B5、FUCA1、GALC、GALNS、GFAP、GLB1、GNE、GNPTAB、GNPTG、GNS、GUSB、HEXA、HEXB、HGSNAT、HYAL1、IDS、IDUA、MCOLN1、MFSD8、MGAT2、MLC1、MOGS、MPDU1、MPI、NAGLU、NEU1、NOTCH3、NPC1、NPC2、PEX1、PEX12、PEX14、PEX2、PEX26、PEX3、PEX5、PEX6、PEX7、PEX10、PEX13、PEX16、PEX19、PGM1、PLP1、PMM2、PPT1、PSAP、RFT1、RNASEH2A、RNASEH2B、RNASEH2C、SAMHD1、SDHA、SGSH、SLC17A5、SLC35A1、SLC35A2、SLC35C1、SMPD1、SUMF1、TMEM165、TPP1、TREX1。
在一些实例中,突变发生在与伴癫痫的症状性障碍关联的基因中,伴癫痫的症状性障碍包括例如少年肌阵挛性癫痫、儿童失神性癫痫、良性罗兰多癫痫(benign rolandicepilepsy)、伦诺克斯-加斯托综合征、德拉韦综合征、大田原综合征、韦斯特综合征等。突变可发生在以下基因中的一个或多个中:ATP2A2、ATP6V0A2、BCKDK、CACNA1A、CACNB4、CCDC88C、DYRK1A、HERC2、KCNA1、KCNJ10、KIAA1279、KMT2D、LBR、LGI1、MAPK10、MECP2、MEF2C、NDE1、NIPBL、PANK2、PIGV、PLA2G6、RAI1、RBFOX1、SCN8A、SERPINI1、SETBP1、SLC1A3、SLC4A10、SMC3、SYNGAP1、TBX1、TSC1、TSC2、TUSC3、UBE3A、VPS13A、VPS13B。
在一些实例中,突变发生在与偏头痛的发生关联的基因中。突变可能发生在以下基因中的一个或多个中:ATP1A2、CACNA1A、NOTCH3、POLG、SCN1A、SLC2A1。
在一些实例中,突变发生在与过度惊骇(Hyperekplexia)关联的基因中。突变可能发生在下列基因中:ARHGEF9、GLRA1、GLRB、GPHN、SLC6A5。
在一些实例中,突变发生在与先天性代谢缺陷相关的基因中,该先天性代谢缺陷包括例如碳水化合物代谢障碍、氨基酸代谢障碍、尿素循环障碍、有机酸代谢障碍、脂肪酸氧化和线粒体代谢障碍、卟啉代谢障碍、嘌呤或吡啶代谢障碍、类固醇代谢障碍、线粒体功能障碍、过氧化物酶体功能障碍和溶酶体贮积障碍。突变可能发生在以下基因中的一个或多个中:ABAT、ABCC8、ACOX1、ACY1、ADCK3、ADSL、ALDH4A1、ALDH5A1、ALDH7A1、AMT、ARG1、ATIC、ATP5A1、ATP7A、ATPAF2、BCS1L、BTD、C12ORF65、CABC1、COQ2、COQ9、COX10、COX15、DDC、DHCR7、DLD、DPYD、ETFA、ETFB、ETFDH、FOLR1、GAMT、GATM、GCDH、GCSH、GLDC、GLUD1、GLUL、HPD、HSD17B10、HSD17B4、KCNJ11、L2HGDH、LRPPRC、MGME1、MMACHC、MOCS1、MOCS2、MTHFR、MTR、MTRR、NDUFA1、NDUFA2、NDUFAF6、NDUFS1、NDUFS3、NDUFS4、NDUFS7、NDUFS8、NDUFV1、PC、PDHA1、PDHX、PDSS1、PDSS2、PGK1、PHGDH、POLG、PRODH、PSAT1、QDPR、RARS2、SCO2、SDHA、SLC19A3、SLC25A15、SLC46A1、SLC6A8、SUCLA2、SUOX、SURF1、TACO1、TMEM70、VDAC1。
已知芬氟拉明抑制5-羟色胺(serotonin)的再摄取,并由于破坏5-羟色胺的囊泡贮积(vesicular storage)而触发5-羟色胺在脑中的释放。来自最新研究的数据提供了芬氟拉明是σ-1受体的正向变构调节剂(positive allosteric modulator)的证据。在本发明中,芬氟拉明的作用机制使芬氟拉明适于治疗癫痫亚型,例如,德拉韦综合征、伦诺克斯-加斯托综合征或多泽综合征。根据本发明的另一方面,提供了一种通过将有效剂量的芬氟拉明与生酮饮食向患者组合给药、以刺激或调节所述患者脑中的一个或多个靶标的方法,其中所述一个或多个靶标选自由伴侣蛋白(chaperone protein)、生物胺转运体(bioaminetransporter,BAT)和5-HT受体组成的组。
在本发明的方法中,可以采用芬氟拉明作为癫痫亚型的治疗中的单药疗法,该癫痫亚型例如德拉韦综合征、伦诺克斯-加斯托综合征或多泽综合征的。可替代地,芬氟拉明可以与诸如抗惊厥药的一种或多种共治疗剂同时、顺序或分开地共同给药。优选的共治疗剂可以选自由卡巴西平(carbamazepine)、乙琥胺(ethosuximide)、磷苯妥英(fosphenytoin)、拉莫三嗪(lamotrigine)、左乙拉西坦(levetiracetam)、苯巴比妥(phenobarbital)、普罗加比(progabide)、托吡酯(topiramate)、司替戊醇、丙戊酸、丙戊酸盐(valproate)、维拉帕米(verapamil)、和苯二氮卓类(benzodiazepines)组成的组,苯二氮卓类诸如氯巴占、氯硝西泮、地西泮(diazepam)、氯氟卓乙酯(ethyl loflazepate)、劳拉西泮(lorazepam)、咪达唑仑(midazolam)。还考虑使用共治疗剂的药学可接受盐。然而,卡巴西平、奥卡西平(oxcarbazepine)、拉莫三嗪、苯妥英(phenytoin)和氨己烯酸(vigabatrin)通常在德拉韦综合征中是禁忌的,因为它们倾向于使癫痫发作更坏,而不是更好。
根据本发明的方面,提供了一种通过向受试者给药治疗有效剂量的芬氟拉明活性剂来治疗受试者的方法,所述受试者例如诊断患有癫痫亚型(例如,德拉韦综合征、伦诺克斯-加斯托综合征或多泽综合征)的患者。芬氟拉明活性剂包括芬氟拉明、或者其药学可接受盐或缀合物。这样,芬氟拉明可以以游离碱的形式给药、或以药学可接受盐的形式给药,该药学可接受盐例如选自由盐酸盐、氢溴酸盐、氢碘酸盐、马来酸盐、硫酸盐、酒石酸盐、醋酸盐、柠檬酸盐、甲苯磺酸盐、琥珀酸盐、甲磺酸盐和苯磺酸盐组成的组。其他说明性药学可接受盐可在伯杰(Berge)等,J.Pharm Sci.(1977)68(1):1-19中找到。
本发明的方法中使用的芬氟拉明可根据本领域技术人员已知的任何药学可接受工艺来生产。以下文件中提供了用于合成芬氟拉明的过程的实施例:GB1413070、GB1413078和EP441160。
在本发明的实施方案中,可以采用任何有效剂量的芬氟拉明。在一些情况下,出人意料的是,本发明人已经发现低剂量的芬氟拉明是有效的,特别是对于抑制或消除德拉韦综合征、伦诺克斯-加斯托综合征或多泽综合征患者的癫痫发作是有效的。此外,与成人肥胖症的治疗所需的剂量(通常为60-120mg/天)相比,出人意料的低剂量芬氟拉明在降低食欲和对碳水化合物的渴望中也是有效的。武特曼(Wurtman)等人描述了使用30mg/天的右芬氟拉明治疗(dexfenfluramine)的成年人的碳水化合物渴望降低(Int.J.Eat.Disord.,1985,4:89-99)。在实验动物(加拉蒂尼(Garratini)等.1988)和人类(古道尔(Goodall)等.1992)中,右芬氟拉明的总体厌食作用大于左芬氟拉明。当在一组16名人类受试者中直接比较时,发现右芬氟拉明的厌食功效是外消旋混合物芬氟拉明的两倍。30毫克剂量的右芬氟拉明将食物摄入量抑制到与60毫克芬氟拉明相同的程度,表明外消旋混合物的厌食活性的较大部分在于d-异构体(西尔弗斯通(Silverstone)T.,药物(Drugs)43(6):820-836.1992)。因此,与30mg/天剂量的右芬氟拉明等效的剂量将是约60mg/天的外消旋芬氟拉明,其用于本文公开的制剂中。因此,在本发明的优选实施方案中,最大日剂量为不超过约26mg/天的作为游离碱或药学可接受盐的芬氟拉明(例如,30mg/天的盐酸芬氟拉明),采用小于约0.8mg/kg/天、0.7mg/kg/天、0.6mg/kg/天、0.5mg/kg/天、约0.4mg/kg/天、约0.3mg/kg/天、约0.25mg/kg/天或约0.2mg/kg/天至约0.1mg/kg/天、约0.05mg/kg/天或约0.01mg/kg/天的日剂量。换句话说,优选剂量不超过约30mg/天,并且小于约1至约0.01mg/kg/天。该剂量小于为减轻体重而建议给药的芬氟拉明的日剂量。
芬氟拉明活性剂可以作为适当的制剂给药,该制剂包括药学可接受媒介物(vehicle)中的芬氟拉明活性剂。在一些方面中,该方法可以包括:以范围在1mg/ml至5mg/ml的以游离碱、或者药学可接受盐或缀合物存在的芬氟拉明的浓度给药芬氟拉明活性剂;和以一天一次、一天两次、一天三次或一天四次为基础在几天、几周或几个月的时间段内将所述芬氟拉明活性剂提供给患者,其中该剂量以0.2mg/kg/天或0.7mg/kg/天、直到最大量26mg每天的芬氟拉明的水平提供给患者,芬氟拉明作为游离碱、或者在药学可接受盐或缀合物中。该剂量优选地以十二小时间隔一天两次地提供,由此,本发明的一个方面是在10天、20天、30天、50天、100天或更长的时间段内将惊厥发作频率降低50%以上、60%以上、70%以上、80%以上、90%以上、95%以上、或完全消除患者的癫痫发作。
根据本发明的另一方面,受试者可以正在进行生酮饮食,或可以开始进行生酮饮食。“进行生酮饮食”是指患者以生酮餐的形式消耗营养,生酮餐诸如生酮早餐、午餐和晚餐。主要由脂质组成的生酮饮食已被用于治疗儿童的癫痫,特别是肌阵挛性和运动不能性癫痫发作(怀尔德(Wilder),R.M.酮尿对癫痫病程的影响.Mayo Clin.Bull.,1921,2:307-ff),并且已证明在对常规药理学手段是难治性的情况下有效(弗里曼(Freeman),J.M.,E.P.G.瓦伊宁(Vining).顽固性癫痫.Epilepsia,1992,33:1132-1136)。自二十世纪90年代初以来,当对儿童的调查研究和临床试验证明了生酮饮食在耐药性患者和特定小儿癫痫综合征中的功效时,全世界对使用生酮饮食以管理成人耐药性癫痫的兴趣日益增加。约1,950万患有癫痫的人具有药物无法控制的癫痫发作。也存在普遍认同,一旦患有婴儿痉挛(韦斯特综合征)、伦诺克斯-加斯特综合征、德拉韦综合征、安格尔曼综合征(特别是伴LGIT)和肌阵挛性-站立不能性癫痫的患者的癫痫对于药物治疗而言变得难治,则这些患者受益于饮食疗法试验(南吉亚(Nangia)等,2012,蒂贝尔(Thibert)等,2012).Williams等,先前引用(op.cit.))。生酮饮食疗法为癫痫持续状态的管理提供了所需的辅助策略(adjunctstrategy)。它具有与其他并行治疗快速且协同地工作的潜在优势,在密切跟进的情况下,在受控的重症监护病房设置中相对容易启动、监控和维持,并且它不会导致在使用用于治疗难治性癫痫持续状态的麻醉药时所看到的血液动力学不稳定性。
游离脂肪酸或甘油三酸酯的口服给药或不经肠道给药均可增加血酮,条件是碳水化合物和胰岛素低以防止脂肪组织中的再酯化。喂食由70%玉米油、20%酪蛋白水解物(casein hydrolysate)、5%纤维素、5%麦考伦(McCollums)盐混合物组成的饮食的老鼠产生约2MM的血酮。用猪油代替玉米油将血酮提高至约5mM(费契(Veech),未公开)。尽管纤维素是葡萄糖聚合物,因此是碳水化合物,但它不能被人类消化,因而未从生酮饮食中排除。不可消化的碳水化合物通常被称为膳食纤维,并被用作填充剂(bulking agent)以及增稠剂。
万豪医疗服务公司(Marriott Corp.Health Care Services)的1987年8月修订的小儿饮食手册(Pediatric Diet Manual)推荐传统1500卡路里/天的生酮饮食的示例适于4-6岁的癫痫儿童,对于每克的组合碳水化合物和蛋白质,该生酮饮食含有3:1至4:1g的脂肪。在三餐生酮饮食的每餐中,患者必须吃掉48至50g脂肪,仅6g蛋白质和10至6.5g碳水化合物。实践中,这意味着在每餐中,儿童必须吃掉相当于每天32g人造黄油(约1/4支)和喝掉92g浓奶油(约100毫升),主要包含中等链长度的甘油三酸酯。该饮食迫使人体代谢脂肪,而不是碳水化合物来获取能量,从而提高血液中乙酰乙酸盐(acetoacetate)和D-3-羟基丁酸盐(D-3-hydroxybutyrate)的水平。这些化合物被称为“酮体”,因此术语“生酮”用来描述该饮食。
饮食坚持和依从性仍然是成功的生酮饮食实施以及适当受控的临床中功效评估的明显障碍。对11份成人生酮饮食研究的荟萃分析(meta-analysis)报道了,对于所有类型的生酮饮食的组合坚持率为45%,对于经典生酮饮食(ketogenic diet,KD)为38%,对于修改的阿德金斯饮食(Adkins diet)(通常由净重(net)10-20g/天的碳水化合物限制组成--相当于脂肪与蛋白质和碳水化合物的比例为1-2:1)为56%(叶(Ye)等,J.Clin.Neurol.2015Jan;11(1):26-31)。类似地,最近的用生酮饮食治疗的139位成人患者的观察性研究,48%(139位中的67位)中断该饮食(39%)或在初次跟进后丢失(9%),约一半的患者以难以依从或限制性为停止的原因(威廉姆斯等,先前引用)。大脑占人体葡萄糖消耗的约20%,并严格调节其所需的能量供应,且生酮饮食模拟饥饿(即,被剥夺作为能量来源的葡萄糖来源),导致身体转变为称为酮症的代谢状态(代谢作为主要能量来源的脂肪)。生酮饮食的不依从或放弃的一个原因是碳水化合物渴望,这是由导致对食物的渴望的大脑信号造成的,该食物含有被感知为缺乏的营养。
通常,人体以碳水化合物为燃料;摄入的碳水化合物被分解为葡萄糖,葡萄糖主要被运输并用作能量或作为糖原存储在肝和肌肉组织中。当被剥夺膳食碳水化合物时(对于成人,通常低于50g/天),肝脏会成为唯一的葡萄糖提供者,以供养人体器官,尤其是大脑,如上所述,大脑占总能量消耗的~20%。然而,在一些患者中,感知到的能量失衡会导致对碳水化合物的渴望,有时甚至是强烈的渴望。在一些患者中,随着身体和大脑适应新的能量平衡,渴望随着时间而消退,然而,在其他患者中,对碳水化合物的渴望继续。要成功进行生酮饮食,患者必须避免或严格限制所消耗的碳水化合物的量;不坚持的后果是,人体转变回到葡萄糖代谢且抗癫痫发作的益处消退,并且渴望继续。
大脑在兴奋和抑制之间保持平衡,这种平衡通过两种主要的神经递质(neurotransmitter)、即兴奋性谷氨酸和抑制性GABA调节。在中风、癫痫发作和神经退行性变中发生的过量谷氨酸信号传导会导致兴奋性中毒(excitotoxicity)。尽管生酮饮食的确切作用机理尚未很好理解,但一个长期存在的假设是,酮体可能直接充当药理剂(pharmacological agents),虽然尚未阐明可能的靶标。最近,发现酮体乙酰乙酸盐在生酮饮食期间预期的浓度下,抑制囊泡谷氨酸转运体(vesicular glutamate transporter)VGLUT2将谷氨酸转运到突触囊泡(synaptic vesicle)中(朱基(Juge)N等,Neuron.,2010,68:99-211)。在暴露于乙酰乙酸盐的培养神经元中,谷氨酸释放减少;因此,乙酰乙酸对谷氨酸信号传导的抑制可能会降低神经元的兴奋性。较早的工作表明抑制性神经递质GABA的产生增加可能是因为由生酮饮食产生的大脑代谢变化造成的。不受理论的束缚,假设当有酮体可用时,通过谷氨酰胺的谷氨酸再循环变得更有效,并且这可以改进抑制性神经传递的GABA再合成,甚至超过其影响兴奋性神经传递的谷氨酸重新包装。尽管在啮齿类动物中尚未观察到总的大脑GABA水平的升高,但预计较高的GABA产生会增加大脑中的抑制性信号传导。GABA信号传导的这些变化可以补充乙酰乙酸盐产生的谷氨酸信号传导的假想变化(路塔斯(Lutas)和耶伦(Yellen),Trends Neurosci.,2013,January;36(1):32–40)。
然而,为了对该目的有效,患者必须严格遵守该饮食。该饮食中包括维生素和矿物质补充剂以使该饮食营养全面,因为该饮食脂肪含量非常高、蛋白质含量低,并需要几乎消除碳水化合物。每个患者的饮食都是基于患者的年龄、规格(size)和活动水平而精确(mathematically)计算的。患者通常遵循该饮食一到两年,在那时慢慢戒断至正常饮食。已发现该饮食对癫痫儿童特别有效。主要缺点是该饮食不是非常适口(palatable),且患者的依从性要求患者及其家人的完全承诺。此外,在长期使用中,该饮食的高脂肪含量可能会增加血管疾病的风险,例如动脉粥样硬化。
在本发明中,可以向患有德拉韦综合征的患者单独地或与非药物疗法组合给药有效剂量的化合物。组合治疗方法是其中可以将具有有效剂量的化合物的制剂与附加疗法组合使用的方法。如本文所用,药剂、例如芬氟拉明的剂量是指含有该药剂的主题(subject)制剂的治疗有效剂量。术语“药剂”、“化合物”和“药物”在本文中可互换地使用。在一个实施方案中,具有有效量活性剂的芬氟拉明制剂可以单独给药或连同诸如生酮饮食的低碳水化合物饮食一起给药。如本文所用,“有效量”是在单一疗法或组合疗法中以一种或多种剂量给药于个体时,有效使癫痫发作的发生降低约20%、至少约30%、至少约40%、至少约50%、至少约60%、至少约70%、至少约80%或至少约90%的主题化合物的量。在一些实施方案中,主题方法还包括与生酮饮食附随地共同给药一定剂量的芬氟拉明。在一些实例中,该方法包括向受试者、例如进行生酮饮食的受试者给药化合物。在一些实施方案中,该方法还包括向患者给药生酮饮食。
术语“共同给药”和“与...组合”包括在不存在特定时间限制内,同时地、并行地或顺序地给药两种以上的治疗剂或疗法。在一个实施方案中,治疗剂、例如一定量的芬氟拉明,与另一疗法、例如生酮饮食同时存在于受试者体内,或者同时发挥生物学作用或治疗作用。在一个实施方案中,治疗剂、例如有效剂量的芬氟拉明和非药物疗法、例如生酮饮食,同时给药。有效剂量的芬氟拉明制剂可以与生酮饮食餐同时给药。在其他实施方案中,治疗剂和非药物疗法在不同时间给药。可以例如在生酮饮食餐之前或之后给药有效剂量的芬氟拉明制剂。在某些实施方案中,可以在第二治疗剂给药或疗法之前(例如,分钟、15分钟、30分钟、45分钟、1小时、2小时、4小时、6小时、12小时、24小时、48小时、72小时、96小时、1周、2周、3周、4周、5周、6周、8周或12周之前)、与第二治疗剂给药或疗法附随地、或在第二治疗剂给药或疗法之后(例如,5分钟、15分钟、30分钟、45分钟、1小时、2小时、4小时、6小时、12小时、24小时、48小时、72小时、96小时、1周、2周、3周、4周、5周、6周、8周或12周之后)给药第一治疗剂或疗法。
治疗药物或非药物疗法的“附随(concomitant)给药”是指在本发明的药物和非药物疗法都将具有治疗作用的时间时化合物的给药和其他疗法。此类附随给药可以涉及相对于非药物疗法给药并行的(即同时)、之前或之后给药药物。化合物的给药途径可以变化,其中在下面描述代表性的给药途径。本领域普通技术人员将毫无困难地确定本公开的特定药物或疗法的适当给药时机、顺序和剂量。
在一些实施方案中,主题化合物、例如芬氟拉明,和至少一种额外的化合物或疗法、例如生酮饮食餐,在彼此的24小时内,例如在彼此的12小时内、在彼此的6小时、在彼此的3小时内、或在彼此的1小时内给药于受试者。在某些实施方案中,化合物和疗法在彼此的1小时内给药。在某些实施方案中,化合物和疗法基本同时给药。基本同时给药是指在彼此的约10分钟或少于10分钟内,例如在彼此的5分钟以下、或1分钟以下,将化合物和疗法给药于受试者。
本发明的方法可以在任何适当的受试者上实践。本发明的受试者可以是“哺乳动物(mammal)”或“哺乳类动物(mammalian)”,其中这些术语被广泛用于描述哺乳纲(classmammalia)内的生物,哺乳纲包括食肉目(例如,狗和猫)、啮齿目(例如,小鼠、豚鼠和大鼠)和灵长目(例如,人类、黑猩猩和猴子)。在一些实例中,受试者为人类。该方法可以应用于两种性别的和处于任何发育期(即,新生儿、婴儿、少年、青少年、成人)的人类受试者,其中在某些实施方案中,人类受试者是少年、青少年或成人。尽管本发明可以应用于来自人类受试者的样品,但是应当理解,该方法也可以在来自其他动物受试者的样品上(即,在“非人类受试者”中)实施,例如但不限于鸟类、小鼠、大鼠、狗、猫、家畜和马。
本发明的方法可以在任何适当诊断的患者上实践。在本发明的典型实施方案中,患者为成人,或年龄为约18岁以下、约16岁以下、约14岁以下、约12岁以下、约10岁以下、约8岁以下、约6岁以下、或约4岁以下至约0个月以上、约1个月以上、约2个月以上、约4个月以上、约6个月以上、或约1岁以上。因此,诊断的患者在治疗时通常为约一个月以上。
在本发明的方法中给药的芬氟拉明的剂量可以以任何药学可接受剂型配制,即制剂,包括但不限于口服剂型,诸如包括口服崩解片(orally disintegrating tablet)的片剂、胶囊剂、锭剂、口服溶液或糖浆剂、口服乳剂、口服凝胶剂、口服膜剂(film)、口腔液体剂、和例如用于混悬剂的散剂等;可注射剂型;透皮剂型,诸如透皮贴剂、软膏、乳霜;吸入剂型和/或经鼻、经直肠、经阴道给药的剂型。这些剂型可以配制成一天一次给药,或每日多次给药(例如,一天2次、3次或4次给药)。
在本发明的方法中使用的芬氟拉明的剂型可以是液体剂型。在一些实例中,液体剂型是水性液体剂型。液体剂型可作为溶液剂、混悬剂或乳剂口服获得。在本发明的一方面中,通过使用用于精确测量液体制剂的口腔刻度注射器,将芬氟拉明制剂作为液体制剂给药。在一些实例中,该制剂为基本上不含油、非水性溶剂和不溶解的颗粒。
液体口服溶液剂型可以适于基于受试者的状况、性别和总体疾病状态而向受试者给药治疗有效剂量的芬氟拉明。在一些实例中,液体口服溶液剂型可以适于基于年龄给药(dosing)或基于体重给药。口服溶液剂型可以适于小儿和成人人群。在一些实例中,口服液体剂型由经受吞咽困难的患者使用。
根据本发明,提供了含有芬氟拉明活性剂的治疗有效剂量的制剂。在一些实例中,该制剂可以包含适于单独给药的有效量的治疗剂,以提供治疗作用。治疗有效剂量可以是可测量和给药的任何可变的液体剂量体积。在一些实例中,剂量体积的范围包括适于向小儿人群给药的体积。在某些实施方案中,剂量体积的范围包括0.2ml至12ml,例如0.5ml至6ml。在一些实例中,本发明的剂量体积与生酮饮食在碳水化合物的卡路里含量方面是相容的。
在本发明的方法中采用的芬氟拉明的剂型,可以通过将芬氟拉明活性剂与一种或多种药学可接受的稀释剂、载体、佐剂、缓冲剂和所需赋形剂等以任何混料(admixing)顺序、并以药物制剂领域的技术人员已知的方式组合来制备。液体剂型可以包括一种或多种可选的药物赋形剂,该药物赋形剂包括助悬剂(例如,树胶、黄原胶、纤维素和表面活性剂)、增溶剂(例如,乙醇、水、甘油、PEG和丙二醇)、表面活性剂(例如,十二烷基硫酸钠、司盘(Spans)、吐温(Tweens)和十六烷基吡啶(cetyl pyridine))、防腐剂(preservative)(例如,羟苯(paraben)、山梨酸、苯甲酸)、抗氧化剂(例如,抗坏血酸、焦亚硫酸钠)、抗结块剂、防泡剂(例如,二甲基硅油)、螯合剂(例如,EDTA)、着色剂、风味剂(flavor)、例如酸化剂的风味助剂(flavor-aid)(例如,柠檬酸或酒石酸)、或凉味剂(cooling agent)(例如,薄荷醇、木糖醇)或药学相容的媒介物或载体。
根据本发明的实施方案的制剂的一个方面是甜味剂。术语“甜味剂”是指被添加到根据本发明的制剂中以使制剂更适口的甜味剂,优选天然或人造甜味剂。在某些实施方案中,为芬氟拉明制剂选择的甜味剂以及制剂中甜味剂的量与生酮饮食相容。根据本发明的实施方案,每100g制剂中甜味剂的碳水化合物卡路里含量在来自碳水化合物的零至40卡路里。甜味剂可以是高强度低卡路里或零卡路里的甜味剂。例如,根据本发明的甜味剂可以包括许阿斯巴甜、糖精、乙酰磺胺酸钾、环磺酸盐(cyclamates)、三氯蔗糖、以及许多其他合成甜味剂;天然甜味剂,诸如甜菊糖和索马甜;糖醇(多元醇),诸如甘露醇、木糖醇、麦芽糖醇、赤藓糖醇和异麦芽酮糖醇);以及糖类甜味剂,例如蔗糖/水溶液(USP蔗糖糖浆,约85重量%的蔗糖和约15重量%的水)、麦芽糖、玉米糖浆、果糖糖浆和相关水果糖浆甜味剂以及其他。制剂中甜味剂的浓度可以在0.1%(1mg/ml)至4%(40mg/ml)的范围内。
制剂还可包括调味剂。调味剂可以增加制剂的总体风味、味道和合意性(desirability)。适当的调味剂包括例如巧克力、薄荷、留兰香、葡萄、樱桃、草莓、橙子(orange)、柠檬、沙士、西瓜等,或在所需pH或温度下稳定的任何其他调味剂。剂型可以包括浓度在0.05%(0.5mg/ml)至1%(10mg/ml)范围内、诸如在0.05%(0.5mg/ml)至0.1%(1mg/ml)范围内的调味剂。
在一些实例中,制剂包括pH改性剂,例如缓冲剂。pH改性剂涉及调节、改变或调整制剂的pH的任何药学上适当的试剂。缓冲剂是指一种或多种任何药学上适当的试剂,当与主题制剂一起配制或递送时,其起到维持制剂的pH的作用。缓冲液的浓度可以是0.01摩尔到0.5摩尔,例如0.03M。适当的pH范围可以包括4.5至6.5的pH,诸如4.5至5.5、以及5.0至5.1。
适当的pH改性剂可以包括但不限于碳酸氢钠、碳酸氢钾、氢氧化镁、氧化镁、乳酸镁、葡萄糖酸镁、其他镁盐、氢氧化铝、氢氧化铝/碳酸氢钠共沉淀物、氨基酸和缓冲液的混合物、甘氨酸铝和缓冲液的混合物、氨基酸的酸式盐和缓冲液的混合物、以及氨基酸的碱式盐和缓冲液的混合物。额外的pH改性剂包括但不限于碳酸镁、硅酸镁、乙酸钙、甘油磷酸钙、氯化钙、氢氧化钙、乳酸钙、碳酸钙、碳酸氢钙(calcium bicarbonate)和其他钙盐。感兴趣的缓冲剂可以包括柠檬酸钠(与柠檬酸组合)、酒石酸钠(与酒石酸组合)、乙酸钠(与乙酸组合)、碳酸钠(与碳酸氢钠组合)、多磷酸钠、多磷酸钾、焦磷酸钠、焦磷酸钾、磷酸氢二钠、磷酸氢二钾、磷酸三钠、磷酸三钾、偏磷酸钾。在某些实施方案中,根据例如目标pH,缓冲剂是柠檬酸盐缓冲剂或柠檬酸盐-磷酸盐缓冲剂。在一些实例中,缓冲剂为柠檬酸三钾和柠檬酸。示例性缓冲剂包括柠檬酸/磷酸盐缓冲剂、醋酸盐缓冲剂、柠檬酸缓冲剂或磷酸盐缓冲剂。
额外地,可将各种添加剂掺入此类液体剂型中,以增强稳定性、无菌性和/或等渗性(例如,糖、氯化钠等)。可以添加抗微生物防腐剂,诸如抗霉素(ambicin)、抗氧化剂、螯合剂和附加缓冲剂。可以将制剂缓冲至防腐剂的最佳活性范围内的pH。例如,各种抗细菌剂和抗真菌剂,诸如羟苯(对羟基苯甲酸酯或4-羟基苯甲酸酯)、氯丁醇、苯酚和山梨酸等可以增强对微生物活动的预防。防腐剂可以是游离酸或钠盐或钾盐。
适合的防腐剂可以包括例如羟苯(羟苯甲酯、羟苯乙酯、羟苯丙酯、羟苯丁酯)、苯扎氯铵(benzalkonium chloride)、苄索氯铵(benzethonium chloride)、苯甲酸、苄醇(benzyl alcohol)、溴硝醇(bronopol)、西曲溴铵(cetrimide)、氯己定(chlorhexidine)、氯丁醇(chlorobutanol)、氯甲酚(chlorocresol)、甲酚、咪脲(imidurea)、苯酚、苯氧乙醇(phenoxyethanol)、苯乙醇(phenylethyl alcohol)、醋酸苯汞(phenylmercuricacetate)、硼酸苯汞(phenylmercuric borate)、硝酸苯汞(phenylmercuric nitrate)、山梨酸钾(potassium sorbate)、苯甲酸钠、丙酸钠、山梨酸、硫柳汞(thimerosal)、羟苯丙酯(propyl paraben)、肉豆蔻基γ-甲基吡啶鎓氯化物(myristyl gama-picoliniumchloride)、羟苯甲酯、羟苯丙酯和季铵化合物(quaternary ammonium compound)。
本制剂可以含有对预防微生物生长有效的量的防腐剂。防腐剂或防腐剂组合,例如作为游离酸或水溶性盐(钠盐或钾盐)的羟苯甲酯和羟苯乙酯的组合(combination),可以以游离酸计范围从0.01%(0.2mg/ml)至0.5%(5mg/ml)、诸如从0.01%(0.1mg/ml)至0.2%(2mg/ml)的浓度存在于制剂中。在一些实例中,制剂包括与0.02%(0.2mg/ml)羟苯乙酯组合的0.2%(2mg/ml)羟苯甲酯;或者与0.01%(0.1mg/ml)羟苯乙酯组合的0.1%(1mg/ml)羟苯甲酯。羟苯甲酯和羟苯乙酯(作为游离酸或水溶性盐)可以以范围从20:1至2:1、例如10:1(羟苯甲酯:羟苯乙酯)的比例存在。
额外地,可以在制剂中使用增稠剂或粘度修饰剂。增稠剂可以用于例如降低混悬剂中的颗粒沉降、降低溢出的可能性、改进灌注期间的控制、改进制剂的制造、改进制剂的适口性、和改进例如通过口腔注射器的制剂的输送。在一些实例中,增稠剂向制剂提供适合的粘度,例如范围在100-200cP的粘度,例如150cP的粘度。
用于本制剂的增稠剂包括聚合的和非聚合的、水混溶性(water-miscible)或水溶性增稠剂。在一些实例中,单独或组合使用的增稠剂包括甲基纤维素、聚乙二醇(PEG)400、甘油、黄原胶、预胶化淀粉(pregelatinized starch)、羟乙基纤维素(250HX)、聚维酮(povidone)和聚维酮K-90等。在一些实例中,增稠剂可以包括乙酰化二淀粉己二酸酯(acetylated distarch adipate)、乙酰化二淀粉磷酸酯(acetylated distarchphosphate)、乙酰化氧化淀粉(acetylated oxidized starch)、乙酰化淀粉、酸处理淀粉、琼脂、海藻酸或其药学可接受盐和衍生物、碱处理淀粉、藻酸铵(ammonium alginate)、阿拉伯半乳聚糖(arabinogalactan)、漂白淀粉(bleached starch)、藻酸钙、角叉菜胶(carrageenan)、糊精、改性淀粉、二淀粉磷酸酯、酶处理淀粉、结冷胶(gellan gum)、瓜尔胶,阿拉伯胶(金合欢树(acacia))、甘油、羟丙基纤维素、羟丙基二淀粉磷酸酯、羟丙基甲基纤维素、羟丙基淀粉、卡拉雅胶(karaya gum)、魔芋胶(konjac gum)、槐豆胶(locust beangum)、甲基乙基纤维素、甲基纤维素、聚环氧乙烷(polyethylene oxide)、单淀粉磷酸酯(monostarch phosphate)、氧化淀粉、果胶、磷酸化二淀粉磷酸酯、加工的麒麟菜属海藻(processed eucheuma seaweed)、海藻酸丙-1,2-二醇酯(propane-1,2-diol alginate)、共聚维酮(copovidone)、海藻酸钠、淀粉辛烯基琥珀酸钠(starch sodiumoctenylsuccinate)、塔拉胶(tara gum)、黄芪胶或其组合。应注意的是,诸如纤维素或衍生纤维素的多糖聚合物也被认为是碳水化合物,然而,考虑到组成纤维素的葡萄糖单元之间的β-缩醛键合,它们不是人类可消化的,并构成了所谓的膳食纤维。例如阿拉伯胶或黄原胶的胶是可溶性膳食纤维,具有复杂的多糖结构,主要对人类和动物是不可消化的。考虑到其不可消化的性质,它们与生酮饮食不相容,因为它们不存在可感知的量的用于代谢的碳水化合物。在一些实施方案中,制剂包括基本上不含可消化性碳水化合物的增稠剂。
增稠剂可以是提供所需粘度范围的任何等级,例如对于1%溶液、粘度范围为1500-5000mPa.s(cP)。在某些实施方案中,增稠剂的浓度在从0.2%(2mg/ml)至5%(50mg/ml)的范围内,诸如从0.3%(3mg/ml)至2%(20mg/ml)的范围,包括0.4%(4mg/ml)至1%(10mg/ml)。
本发明的制剂和剂量是与生酮饮食相容的制剂和剂量。在一些情况下,单剂量的制剂的总碳水化合物卡路里含量在0至5碳水化合物卡路里的范围内。在某些实施方案中,本主题制剂的单一组分具有0至2碳水化合物卡路里的碳水化合物卡路里含量。在一些实施方案中,制剂缺乏营养性/可消化性/血糖性碳水化合物。
在一些实施方案中,制剂是液体芬氟拉明制剂,其包括治疗有效量的芬氟拉明活性剂;和药学可接受媒介物,其中该制剂不含可消化性碳水化合物并且降低碳水化合物渴望,从而促进对生酮饮食的依从性。在一些实施方案中,活性剂是芬氟拉明碱、或其药学可接受盐或缀合物。在一些实施方案中,芬氟拉明活性剂是芬氟拉明药学可接受盐。在一些实施方案中,芬氟拉明药学可接受盐是盐酸芬氟拉明。
在一些实施方案中,液体芬氟拉明制剂是水性制剂。在一些实施方案中,水性制剂包含甜味剂。在一些实施方案中,甜味剂至少是低卡路里甜味剂。在一些实施方案中,甜味剂不是可消化性碳水化合物的来源。在一些实施方案中,甜味剂是零卡路里的甜味剂。在一些实施方案中,甜味剂是三氯蔗糖。
在本发明中,如上所述,芬氟拉明在水性溶液中可以是稳定的。在一些实例中,当芬氟拉明制剂储存在室温下或范围在5℃至60℃的温度下时,可稳定6至60个月。在一些实例中,在4至7的pH范围内配制制剂。制剂可以储存在适合于在其保质期内维持制剂稳定性的任何容器中。
本公开的方法中使用的芬氟拉明的剂量,可以以试剂盒的形式提供,该试剂盒包括用于在本发明的一种或多种方法中使用剂量的说明书。在某些实施方案中,该试剂盒可以额外地包括含有一种或多种共治疗剂的剂型。
还将在以下实施例中说明本发明。
实施例
提出以下实施例以便向本领域普通技术人员提供如何制备和使用本发明的完整公开和描述,并且不旨在限制发明人认为其发明的范围,也不旨在表示以下实验是全部或仅进行的实验。已经努力确保关于所使用的数字(例如量、温度等)的准确性,但是应该考虑一些实验误差和偏差。除非另有说明,否则份数是重量份,分子量是重均分子量,温度是摄氏度,且压力是大气压或接近大气压。
实施例1
药物产品[芬氟拉明,口服溶液]的组分
原料药(drug substance)
原料药与赋形剂的相容性
已经通过开发稳定性研究证实了溶液中的盐酸芬氟拉明与制剂赋形剂的相容性。在长期和加速存储条件下评估了包括各种成分组合的多种制剂。此外,到目前为止,来自预期商业制剂的符合ICH(国际人用药品注册技术协调会)的稳定性研究的结果进一步证明了原料药与制剂赋形剂的相容性。
原料药的理化特性
盐酸芬氟拉明原料药的理化性质总结如下。与药物产品的性能和可制造性有关的性质讨论如下。
固体状态
盐酸芬氟拉明是作为具有针状形貌(morphology)的单一形式(形式1)存在的晶体材料。原料药在固体状态下是化学稳定的和物理稳定的,并且在多晶型物(polymorph)筛查研究、或加速和长期稳定性研究中未观察到其他多晶型物。
水溶性
原料药水溶性根据pH而适度变化。在25℃时,溶解度范围从pH 1.7时的约25mg/ml到pH 6.7时的50mg/ml以上。溶解度比其在药品中的浓度高10倍以上,在包括长期冷藏的正常储存条件下,不太可能发生原料药从溶液中沉淀出来。在5℃下储存超过1个月并在-20℃下储存几天的药物产品制剂在芬氟拉明试验中没有显示出任何显著的变化。
在生理温度(37℃)下以及1.7至6.7的pH范围中的溶解度在54mg/ml和96mg/ml之间变化。
粒径
盐酸芬氟拉明原料药是未微粉化的(non-micronized)。表1中列出了从五个药品生产质量管理规范(GMP)批次(安内科斯(Onyx)制造的两个临床批次,和阿特(Aptuit)制造的三个注册批次)获得的粒度参数范围。由于盐酸芬氟拉明相对于其在制剂中的浓度的高溶解度,并不预期粒径对药物产品制造工艺具有明显影响。通过始终证明原料药在制剂媒介物中快速溶解的制造经验确定了这一点。此外,与相同批次的微粉化部分相比,评估了具有60μm的中值粒径(D50)和250μm的百分之九十(D90)的实验批次原料药,并且在完全溶解于制剂媒介物中所需的时间内未观察到差异。
表1.盐酸芬氟拉明临床和注册批次的粒径范围
溶液稳定性
强制降解研究表明,药物活性成分(active pharmaceutical ingredient,API)在水性溶液中非常稳定。在早期开发期间,研究了浓度在0.5mg/ml至5mg/ml范围内的盐酸芬氟拉明的缓冲水性溶液的热稳定性。表2、表3和表4中提供的数据显示了,当在60℃、pH 6.8下储存时,盐酸芬氟拉明稳定至少6个月。表2.盐酸芬氟拉明0.5mg/ml缓冲水性溶液pH 6.8的稳定性
表3.盐酸芬氟拉明2.5mg/ml缓冲水性溶液pH 6.8的稳定性
表4.盐酸芬氟拉明5mg/ml缓冲水性溶液pH 6.8的稳定性
赋形剂
芬氟拉明口服溶液制剂中的赋形剂包括防腐剂、增粘剂(viscosity buildingagent)、甜味剂、缓冲剂和调味剂。制剂中使用的所有赋形剂均为批准的药物产品中常用的赋形剂。已经通过实时的稳定性数据证明了与溶液中原料药的相容性。
下面,简要讨论可能影响药品制剂的性能和可制造性的各赋形剂的性质。
羟苯甲酯钠
羟苯甲酯钠(对羟基苯甲酸甲酯钠)是美国药典-国家处方集(USP-NF)和欧洲博士专著(Ph.Eur.monographs)的药典赋形剂。它是4-羟基苯甲酸甲酯的钠盐。羟苯甲酯是通常作为游离酸和钠盐在口服的、局部的和可注射的药物制剂中使用的防腐剂,并在4-8的pH范围内表现出其抗菌活性。羟苯类防腐剂由于其抗菌作用中已知的协同作用而通常组合使用。
羟苯甲酯钠以0.23%的浓度(相当于0.2%羟苯甲酯)与0.023%羟苯乙酯钠(相当于0.02%羟苯乙酯)在制剂中组合使用。这些防腐剂水平是基于来自防腐剂功效测试(preservative efficacy testing,PET)的数据选择的。芬氟拉明药物产品和安慰剂中羟苯甲酯浓度在非活性成分数据库中列出的食品及药物管理局(FDA)批准的口服药物产品中使用的范围内。
羟苯甲酯及其盐的溶解度取决于pH,在酸中的溶解度较低,而在碱性介质中的溶解度较高。游离酸在水中的溶解度在20℃时为0.25%(400分之一),25℃时为0.30%(生物活性(PubChem))。羟苯甲酯钠具有比游离酸更高的水溶性,并且发现其在药物产品制剂中溶解更快。
如果产品不慎在低温下储存较长时间,则选择羟苯甲酯的钠盐以使防腐剂沉淀的风险最小化。在羟苯甲酯和羟苯乙酯的钠盐(组合)的情况下,在早期开发期间,于5℃储存一个月后,在药物产品制剂中未观察到沉淀迹象。然而,后来在温度循环研究中观察到了一些沉淀(高达20%的羟苯甲酯),没有防腐剂功效的效果。在长期储存稳定性研究中未观察到沉淀。
羟苯甲酯钠在高pH下会水解,但在pH 6以下具有可接受的稳定性。与文献数据(镰田(Kamada),1973)一致,观察到在较高的pH下防腐剂降解增加。优化药品制剂的pH以使防腐剂降解最小化。芬氟拉明口服溶液的预期商业制剂被缓冲至目标pH 5.0,并且在代表性临床制剂中的长达24个月的稳定性数据、和在预期商业制剂中18个月的数据,迄今为止尚未观察到降解水平的显著增加。
羟苯甲酯钠具有中等吸湿性,并且可含有高达5%的水。制造工艺需要校正水含量。
羟苯甲酯钠有轻微灼烈味(burning taste)。
羟苯乙酯钠
羟苯乙酯钠(对羟基苯甲酸乙酯钠)是美国药典-国家处方集和欧洲博士专著的药典赋形剂。它是4-羟基苯甲酸乙酯的钠盐。羟苯乙酯及其钠盐和钾盐在口服和局部药物制剂中用作防腐剂。选择羟苯乙酯用作芬氟拉明口服溶液中的第二羟苯类防腐剂,因为与更常用的羟苯丙酯相比,羟苯乙酯的水溶性更高,因为羟苯的水溶性随链长而下降。
直到最近,羟苯乙酯在美国仅作为游离酸是可用的。在欧洲,游离酸和钠盐都已经是可用的,并且通常用于药物产品中。羟苯乙酯游离酸的溶解度在25℃时为0.08%,在20℃时为0.07%(PubChem)。羟苯乙酯钠具有比游离酸更高的水溶性,并且发现其在药物产品制剂中溶解更快。羟苯乙酯钠以0.023%的浓度与0.23%羟苯甲酯钠在制剂中组合使用。这些浓度是基于来自防腐剂功效测试(PET)的数据而选择的。在研究中还评估了较低的浓度水平。
如果产品不慎在低温下储存较长时间,则选择羟苯类的钠盐以使防腐剂沉淀的风险最小化。在羟苯甲酯和羟苯乙酯的钠盐(组合)的情况下,在早期开发期间,于5℃储存一个月后,在药物产品制剂中未观察到沉淀迹象。然而,后来在温度循环研究中观察到了一些沉淀(高达5%的羟苯乙酯),没有防腐剂功效的效果。在长期储存稳定性研究中未观察到沉淀。
像羟苯甲酯一样,羟苯乙酯在溶液中通过水解而降解。在较高的pH下速率增加。优化药物产品制剂的pH以在保持充足的溶解度的情况下使防腐剂降解最小化,并且在长期稳定性研究中未观察到防腐剂降解产物的明显增加。
使用口服产品的药典防腐剂功效测试(Ph.Eur.5.1.3/USP<51>)确定药物产品制剂中防腐剂系统的性能。
羟乙基纤维素(HEC)
羟乙基纤维素是美国药典、欧洲博士专著和日本协调专著(JP harmonizedmonograph)的药典赋形剂。它通常在药物液体制剂中用作增粘剂(增稠剂)和悬浮剂,并在固体剂型中用作粘合剂和包衣剂(coating agent)。它在芬氟拉明口服溶液中用作增稠剂。
HEC是非离子型半合成水溶性聚合物。它是纤维素的部分取代的聚(羟乙基)醚,可用于不同等级,根据取代度和分子量而具有宽范围的粘度。芬氟拉明口服溶液(250HX)中使用的等级对于1%的水性溶液具有1500-2500mPa.s的规定粘度范围。使用这种高粘度等级可以在0.5%浓度(每毫升5mg HEC)下达到药物产品的目标粘度范围。该量在FDA批准的口服给药产品中的使用范围内。
HEC溶于冷水和热水,但与其他亲水性聚合物一样,在完全溶胀并最终溶解之前,颗粒在被润湿时倾向于聚结。它承受较高浓度的离子组分,并且与制剂中使用的任何其他赋形剂没有已知的不相容性。
HEC溶液是透明、无色且无味的。
HEC在溶液中是稳定的,但在低pH下易受酸水解的影响,这可能导致粘度下降。在碱性条件下可能发生氧化降解。
三氯蔗糖
三氯蔗糖是半合成的甜味剂,其被FDA批准为非营养性甜味剂,并通常用于食品和药物制剂中。三氯蔗糖在芬氟拉明药物产品中以0.1%(1.0mg/ml)的浓度用作甜味剂,该浓度在FDA批准的药物产品中使用的范围内。
三氯蔗糖是水溶性的,其溶液是无色的且具有甜味。
调味剂
樱桃调味粉SN932130(国际香精香料(International Flavors and Fragrances,IFF),荷兰)是用于食品、饮料和药物产品的专用的调味剂混合物。它以0.1%(1mg/ml)在制剂中使用。
柠檬酸钾
柠檬酸钾(柠檬酸三钾)是柠檬酸的三钾盐。它是美国药典-国家处方集和欧洲博士专著的药典赋形剂。它在食品、饮料和药物产品中用作碱化剂或缓冲剂。柠檬酸钾在水中高度可溶,其水性溶液无色且具有盐味。柠檬酸钾是通常被认为安全(generally regardedas safe,GRAS)的材料。
柠檬酸
柠檬酸是GRAS材料,且是美国药典-国家处方集和欧洲博士专著的药典赋形剂。它在食品、饮料和药物产品中用作缓冲剂、酸化剂和风味助剂。它在芬氟拉明口服溶液中与柠檬酸钾组合用作缓冲剂。
柠檬酸容易溶于水,并且具有酸味,酸味的强度取决于浓度。
冲洗用水
欧洲博士专著的冲洗用水(也满足对冲洗用无菌水的要求,美国药典)用作制剂媒介物,占药物产品组成的95%以上。
实施例2
制剂开发[芬氟拉明,口服溶液]
概述
较早的德拉韦综合征(DS)的开放标签临床研究是使用固体口服剂型(含有API和乳糖的共混物(blend)的胶囊)来进行的,该固体口服剂型在给药前分散在液体媒介物中的。随后的开发活动旨在生产用于口服给药的液体制剂,具有单一浓度的盐酸芬氟拉明,其适于跨整个剂量范围内小儿或成人使用,并在室温下储存在多用途瓶中。下面,简要讨论其他目标产品的性质及其合理性。
水性溶液:
通常认为水性口服溶液是针对像新生儿一样小的儿童可接受的剂型。液体剂型为基于年龄或基于体重的给药提供了灵活性。剂量体积的目标范围(0.5ml至6ml)足够小,可以在不损失剂量测量准确性的情况下向幼儿给药。
与其他小儿口服剂型(混悬剂、可分散粉剂或颗粒剂和口服崩解片)相比,口服溶液由于没有固体颗粒,因此具有最低的窒息和误吸(aspiration)风险。
口服溶液也最有可能与胃给药和胃管(naso-gastric tube)给药相容。
水性媒介物提供可接受的口感。
防腐的:
多剂量容器中的水性制剂需要防腐以防微生物生长。
缓冲的:
需要缓冲系统以将pH维持在适当范围内,以保持防腐剂的功效、溶解性和稳定性。
增甜和调味:
通过掩盖来自活性成分和/或其他制剂组分、诸如防腐剂潜在的令人讨厌的味道以及来自缓冲盐的盐味,来对药物产品增甜和调味,以改善小儿患者的可接受性。
略带粘性:
液体制剂粘度的增加减小了意外溢出(spillage)的可能性,并改进了灌注期间的控制以防止溢流(overflow)。还认为通过减小与舌头的接触面积有助于味道掩盖。
未上色:
将红色染料包括在临床产品中,以确保安慰剂和活性溶液盲目(blinding)。然而,对于预期商业制剂,着色剂是不必要的。
最初评估了浓度在0.5和5mg/ml之间的盐酸芬氟拉明。为了准确剂量测量和易于给药,选择2.5mg/ml作为预期商业产品的目标浓度,因为它导致每剂量不少于0.5ml、每剂量不超过6ml的给药体积。后来使用相同的液体制剂来开发两种额外的浓度(1.25mg/ml和5mg/ml),以使3期临床研究中的剂量盲目(dose blinding)。
盐酸芬氟拉明的高水溶性可以以目标产品浓度下配制水性溶液。
强制降解研究表明API在水性溶液中非常稳定。通过在高温和中性pH(pH 6.8缓冲溶液)中进行短期溶液稳定性研究确定了这一点。来自热应力研究的溶液稳定性数据覆盖了从0.5mg/ml到5mg/ml的浓度范围。当储存在60℃下、pH 6.8的水性溶液中时,芬氟拉明稳定至少6个月。
考虑到API水稳定性,因此,制剂开发聚焦在选择功能性赋形剂以赋予本节前面讨论的目标产品性能,和聚焦在为这些赋形剂识别适合浓度范围。
在选择赋形剂中,有意地将选择限制在符合一些患者进行以帮助控制癫痫发作的生酮饮食约束的赋形剂。进行了早期原型(prototype)制剂的短期稳定性研究,以评估API与潜在制剂赋形剂在水性溶液中的相容性。后来,在与临床项目(clinical program)并行的长期稳定性研究中确定了稳定性。可用数据提供了推荐制剂对长期储存稳定的证明。同时确认了稳定性。现有数据提供了所建议的配方可以长期储存稳定的信心。
制剂媒介物的选择
由于原料药在水中的良好溶解性和溶液稳定性,选择了缓冲的水性媒介物。
防腐剂系统的开发
多剂量容器中的水性溶液通常需要抗微生物防腐。针对在芬氟拉明口服溶液原型中的防腐剂功效和稳定性,评估了通常在水性口服液体中使用的两种防腐剂系统(山梨酸类、和羟苯的组合)。也将含有防腐剂系统的制剂与无防腐剂制剂进行了比较。将制剂缓冲到防腐剂的最佳活性范围内的pH。所有五种原型制剂最初都通过了欧洲博士5.1.3中概述的口服液体的防腐标准;也就是说,在14天时,细菌接种至少3个数量级log(3)(three(3))的减少,真菌至少一个数量级log(1)(one(1)log)的减少,而在28天时没有增加。表5总结各单独开发批次的性能。含有山梨酸类的制剂没有表现出比不含防腐剂的制剂更好,表明该防腐剂在制剂中没有提供功能性的防腐剂功效。与不含防腐剂的制剂相比,含有羟苯的制剂对真菌、酵母菌和霉菌更好地防腐,并且更有可能为更苛刻的使用和保质期结束测试提供更好的防腐。因此,选择了基于羟苯类防腐剂的系统进行进一步的开发和优化。
表5.盐酸芬氟拉明口服液原型制剂的防腐剂功效
羟苯(对羟基苯甲酸酯或4-羟基苯甲酸酯)是广谱防腐剂,其在4-8的pH范围内有效。由于协同作用,通常使用组合。在盐酸芬氟拉明溶液的原型制剂中评估了羟苯甲酯和羟苯乙酯的组合。羟苯甲酯是羟苯防腐剂中最常用的且水溶性最好的。羟苯乙酯,较不常用的羟苯,因为与较长链替代品(羟苯丙酯和羟苯丁酯)相比,其水溶性较高,因此将其包括在内。评估了两种水平的防腐剂浓度:0.2%(2mg/ml)羟苯甲酯组合0.02%(0.2mg/ml)羟苯乙酯;和0.1%(1mg/ml)羟苯甲酯组合0.01%(0.1mg/ml)羟苯乙酯。尽管两种水平的原型在时间零点都满足欧洲博士5.1.3的验收标准,但是在低水平原型中始终观察到关于真菌物种的弱点,这表明这些原型可能无法在其预计的保质期结束前保持足够的防腐功效。基于这些数据,为临床制剂选择了较高的防腐剂水平(0.2%的羟苯甲酯和0.02%的羟苯乙酯,以游离酸计)。防腐剂功效的长期稳定性数据确定了所选防腐剂水平的功效。
羟苯甲酯和羟苯乙酯在药物产品制剂中使用的浓度下可溶,溶解度分别为2.5mg/ml和0.8mg/ml。然而,当使用羟苯游离酸时,观察到了溶解防腐剂的困难。还检测到了沉淀物,特别是当原型在2-8℃下储存时。后来用相应的钠盐来代替羟苯甲酯和羟苯乙酯游离酸,因为相应的钠盐在室温下在制剂媒介物中的溶解度更高且溶解(dissolution)更快,并且在开发研究期间或长期稳定性测试期间未观察到盐的溶解或沉淀问题。然而,后来在涉及药品的冷藏(refrigeration)和/或冷冻(freezing)的温度循环研究中观察到了少量的沉淀物(少于羟苯甲酯含量的20%,并少于羟苯乙酯含量的5%)。沉淀物的存在不影响防腐剂功效,所有样品均符合PET验收标准。药物产品储存条件为受控的室温。
增稠剂的选择
将100rpm下的约100-200mPa·s(100-200cP)的粘度范围(使用旋转式主轴粘度计(rotating-spindle viscometer))设定为产品的目标,因为它允许使用口腔注射器的精确输送(不滴落),不会导致潜在制造问题、诸如过多滞留空气,并可能改进制剂的适口性。在评估似乎具有适当粘度的商业可获得的非处方小儿口服液体产品后,选择该范围。测得的产品粘度约为150mPa.s(150cP)。
最初评估了聚合物和非聚合物的水溶混性(water-miscible)或水溶性增稠剂。这些包括聚乙二醇(PEG)400和甘油、黄原胶、预胶化淀粉、羟乙基纤维素和聚维酮的组合。后来,该评估聚焦在亲水性聚合物黄原胶、聚维酮K-90和羟乙基纤维素,因为与例如PEG和甘油的液体赋形剂相比,它们的浓度依赖性粘度(concentration-dependent viscosity)的范围更宽。
为了比较盐酸芬氟拉明制剂中三种聚合物的增粘效果,在缓冲并防腐的媒介物中制备含有各种浓度的各增稠剂的小批次,以确保将考虑到增稠剂与制剂中其他组分之间的任何潜在相互作用。这些实验以1L规模进行。搅拌防腐缓冲的媒介物以产生涡流,并将干粉形式的增稠剂缓慢加入到涡流中。记录了目视观察的各聚合物易分散性、聚结趋势和达到其最大粘度的时间(作为在媒介物中完全溶解的量度),并测量溶液的粘度。
所检查的所有三种赋形剂能够将防腐缓冲的媒介物增稠至所需的粘度范围。羟乙基纤维素花费了最短的时间来水合并达到最终粘度,在喷洒到涡流中时均匀地分散在溶液中,并且花费了约10分钟来水合。黄原胶花费了相似的时间来添加到本体溶液(bulksolution)中,但是花费了近45分钟来达到最终粘度。证明黄原胶在不使用高剪切混合的情况下很难均匀地水合,具有一些未水合的团块间或导致批次废弃。聚维酮由于需要更大量的粉末,因此显著地花费了更长的时间来添加到溶液,并且形成了花费几小时的混合来分散的团块。一经分散,聚维酮花费约10分钟来达到最终粘度。
在为该药物产品开发的高效液相色谱(HPLC)试验方法中,针对干扰评估了具有处于目标粘度所需水平的三种不同增稠剂(黄原胶、聚维酮K-90和羟乙基纤维素250HX分别为0.3%、5%和0.5%)的原型。含有聚维酮的制剂导致HPLC色谱柱的堵塞和损坏,这可能是由于聚合物的相对高的浓度。产物的进一步稀释将导致该方法的较低的灵敏度。
基于粘度数据,在不受芬氟拉明分析方法和加工观察干扰的情况下,选择羟乙基纤维素作为药物产品制剂的增稠剂,因为它最容易分散和水合,溶解最快,且就单位添加量而言粘度增加效率最高。所选浓度为0.5%,其提供约150cP的粘度。
甜味剂的选择
由于生酮(低碳水化合物)饮食可用于癫痫患者,该癫痫患者的癫痫发作对常规抗癫痫药物疗法是难治性的,因此盐酸芬氟拉明口服溶液的甜味剂选择工作聚焦在高强度、零卡路里或低卡路里的甜味剂,包括甘露醇、麦芽糖醇、麦芽糖糊精、山梨糖醇和三氯蔗糖。糖醇(多元醇)由于其潜在的轻泻作用和其在儿童中的可接受性的数据有限的可用性而被迅速淘汰。选择三氯蔗糖是因为它的广泛的可接受性、高甜度,允许以非常低的浓度使用和良好的口感(无后味(aftertaste))。FDA非活性成分数据库中列出的口服液体产品中的三氯蔗糖浓度在0.1%至4%的范围内。盐酸芬氟拉明所选择的浓度(0.1%)在所用范围的低端上,目的是平衡甜味以使产品对小孩适口的需要,防止使其过于吸引人到出现用药过量风险的程度的可能性。
调味剂的选择
在具有草莓、樱桃和橙子风味剂(flavor)的二元混合物中评估了芬氟拉明的相容性。最初的开发原型用橙子风味剂配制而成,因为人们认为柑橘(citrus)风味剂通常具有良好的味道掩盖性能,尤其是在酸性pH值下。然而,在制剂的选定pH范围中,橙子风味剂不能完全溶解,并会引起轻微的浑浊外观。将调味剂变成樱桃,樱桃被证明与制剂相容,并导致改进的清澈外观。樱桃风味剂是广泛可接受的风味剂,具有与广泛的pH范围相容的品尝概要(taste profile)。基于供应商的建议评估了0.05%至0.5%的浓度范围,并且因为对中性或温和风味剂的普遍偏好、尤其是长期使用,因此最初选择了0.05%用于临床产品。将该制剂包装在玻璃瓶中,且最初被赋予短的保质期。浓度后来增加至0.1%。
缓冲系统的选择
在制剂开发研究期间,研究了4.5至6.5的pH范围。根据目标pH,使用柠檬酸缓冲剂或柠檬酸-磷酸盐缓冲剂制备了各种原型。对原型进行了芬氟拉明试验和相关物质、以及防腐剂试验和相关物质的稳定性,并在冷藏长达一个月后在视觉上评估了沉淀。盐酸芬氟拉明在整个pH范围内都是稳定的,但是随着制剂pH的增加,观察到羟苯防腐剂的降解产物具有越来越高的量级。基于初始稳定性数据,将目标pH选择为5.0(范围:4.5-5.5),因为该pH使防腐剂在长期和加速的稳定条件下的降解最小化,而不会在2-8℃下储存的产品中引起沉淀。药物产品制剂中的缓冲组分是柠檬酸三钾和柠檬酸。使用柠檬酸钾代替柠檬酸钠,以避免与羟苯钠盐的同离子效应(common ion effect),该同离子效应可能促使含有柠檬酸钠的原型中的沉淀。
开发稳定性研究
使用选择的组成(composition)在pH范围的两端处、并使用低防腐剂水平和高防腐剂水平进行了开发稳定性研究,以确认临床制剂的稳定性。在制剂开发研究中评估的组成矩阵呈现于表6。
表6.防腐剂的组合的组成
缓冲剂的pH | 羟苯水平 | |
DB501625.024 | 高(pH 5.5) | 高(0.2%w/v甲基、0.02%w/v乙基) |
DB501625.025 | 高(pH 5.5) | 低(0.1%w/v甲基、0.01%w/v乙基) |
DB501625.026 | 低(pH 4.5) | 高(0.2%w/v甲基、0.02%w/v乙基) |
DB501625.027 | 低(pH 4.5) | 低(0.1%w/v甲基、0.01%w/v乙基) |
已经评估了制剂DB501625.024和DB501625.026在长期和加速的储存条件下的稳定性数据。仅评估了低羟苯制剂(DB501625.025和DB501625.027)的防腐剂功效。下面讨论来自这些开发稳定性研究的稳定性数据。
在25℃/60%RH下储存18个月后,在外观、药物试验、防腐剂试验、pH或粘度中未观察到显著变化或趋势。在较高pH的制剂(pH 5.5)中,随着时间的推移,观察到防腐剂降解产物的少量增加,而在低pH的制剂(pH 4.5)中则没有观察到。在该研究的前三个月后,报告的总杂质存在差异。在该研究的前三个月期间,合成杂质未包括在总杂质的总和中。报告的该差异解释了3个月后杂质中可能表现为少量增加的是什么。在整个研究中,未观察到药物相关杂质的水平的趋势或变化。
在加速的储存条件(40℃/75%RH)下储存9个月后,在两个pH值(4.5和5.5)下观察到了粘度的小幅下降。仅在高pH制剂中观察到了防腐剂降解产物的小上升趋势。该增加大于在长期储存条件下观察到的变化,表明较高温度下更快的降解速度。在40℃/75%RH下储存三个月后,在外观、药物试验、防腐剂试验或pH的未观察到显著变化或趋势。
除了防腐剂降解产物的细微差异外,在目标pH范围的低端和高端下制造的两批产品之间的任一条件下均未观察到差异。在该条件下储存1个月后,在2-8℃下储存在玻璃瓶中的样品未表现出沉淀的迹象。
制剂的可接受性和适口性
目标患者人群中的药物产品的可接受性是选择剂型和开发制剂中的主要考虑因素。在跨整个预期给药量范围内,口服溶液适于小儿或成人使用。口服液体制剂的优点是可以测量和给药可变的剂量体积。基于体重或年龄给药的情况下,较小的儿童将获得较小的剂量体积,从而降低不完全摄入的风险,从而降低了剂量不足(under-dosage)的风险。在认识到需要确保预期范围内剂量的准确测量的情况下,做出了努力使剂量体积最小化。单剂量的盐酸芬氟拉明的体积范围在0.4ml至6ml。此外,以下因素会有助于制剂的适口性和可接受性:
芬氟拉明口服溶液为不含任何油、非水性溶剂或不溶解颗粒的水基制剂。因此,预计不会有质地(texture)相关问题。
用通常可接受的风味剂(樱桃)来对制剂增甜和调味。风味剂和甜味剂的浓度低,以保持尽可能接近中性的味道。
原料药的浓度低(2.5mg/ml)。在这样的低浓度下,原料药味道的可检测性通常较低,尤其是在有调味剂和甜味剂的情况下。
该制剂略带粘性,由于在舌头上的接触面积较小(散布较少),通常有助于味道掩盖和适口性。
作为涉及预期商业制剂的临床研究的一部分,在儿童中研究了该制剂的总体可接受性和适口性。在开放标签扩展(研究1503)的最初几个月中,询问了适口性和可接受性问题。
制剂变型的总结
在临床开发期间,使用了两种制剂组合物变型。红色的临床组合物包括1.25、2.5和5mg/ml的盐酸芬氟拉明以及安慰剂。无色的临床组合物包括相同的盐酸芬氟拉明浓度。表7呈现了临床研究中使用的两种制剂的比较。本节还讨论了制剂变型的总结。表7列出了各制剂迄今生产的批次及其用途。
表7:盐酸芬氟拉明口服溶液药物的制剂变型
a 1.25mg/ml、2.5mg/ml、5mg/ml或安慰剂实施例3
剂型的描述
用于口服给药的芬氟拉明溶液是无色的樱桃风味的口服溶液,其在水性媒介物中含有2.5mg/ml的盐酸芬氟拉明(相当于2.16mg/ml的芬氟拉明)。
该溶液容纳在多剂量的高密度聚乙烯(HDPE)瓶中,该瓶盖有防儿童、防拆封(tamper-evident)的封闭物。将使用适当尺寸的口腔注射器来给药该产品,该口腔注射器将与药物产品一起分配。在分配之前,将压入式瓶适配器插入瓶的开口中。
组成
表8中列出了芬氟拉明口服溶液的组成。
表8:芬氟拉明口服溶液的组成
容器封闭物
芬氟拉明口服溶液的主要容器是白色的HDPE圆形瓶,其带有28mm的螺纹颈。可以使用六种不同的瓶尺寸来包装药品。这些瓶尺寸是:30、60、120、250、360和500ml。所有的瓶都是类似的设计和构造。
瓶封闭物是塑料(多层)防儿童安全盖,其带有防撬带(tamper evident band)和印刷的打开说明。
以下表格呈现了其他感兴趣的制剂。
表9:芬氟拉明口服溶液的组成
成分 | 功能 | 量(mg/ml) |
盐酸芬氟拉明 | 活性 | 2.5 |
羟苯甲酯钠 | 防腐剂 | 2.0<sup>b</sup> |
羟苯乙酯钠 | 防腐剂 | 0.2<sup>b</sup> |
三氯蔗糖 | 甜味剂 | 1.0 |
黄原胶 | 增稠剂 | 5.0 |
樱桃调味粉 | 调味剂 | 1.0 |
柠檬酸钾一水合物 | 缓冲剂 | 10.2 |
柠檬酸一水合物 | 缓冲剂 | 5.5 |
冲洗用水 | 溶剂 | Q.S.至1.0ml |
表10:芬氟拉明口服溶液的组成
表11:芬氟拉明口服溶液的组成
成分 | 功能 | 量(mg/ml) |
盐酸芬氟拉明 | 活性 | 2.5 |
羟苯甲酯钠 | 防腐剂 | 2.0<sup>b</sup> |
羟苯乙酯钠 | 防腐剂 | 0.2<sup>b</sup> |
三氯蔗糖 | 甜味剂 | 1.0 |
羟乙基纤维素 | 增稠剂 | 5.0 |
橙子调味粉 | 调味剂 | 1.0 |
柠檬酸钾一水合物 | 缓冲剂 | 10.2 |
柠檬酸一水合物 | 缓冲剂 | 5.5 |
冲洗用水 | 溶剂 | Q.S.至1.0ml |
表12:芬氟拉明口服溶液的组成
成分 | 功能 | 量(mg/ml) |
盐酸芬氟拉明 | 活性 | 2.5 |
羟苯甲酯钠 | 防腐剂 | 2.0<sup>b</sup> |
羟苯乙酯钠 | 防腐剂 | 0.2<sup>b</sup> |
三氯蔗糖 | 甜味剂 | 1.0 |
羟乙基纤维素 | 增稠剂 | 5.0 |
草莓调味粉 | 调味剂 | 1.0 |
柠檬酸钾一水合物 | 缓冲剂 | 10.2 |
柠檬酸一水合物 | 缓冲剂 | 5.5 |
冲洗用水 | 溶剂 | Q.S.至1.0ml |
前面仅说明了本发明的原理。应当理解,本领域的技术人员将能够设计出各种布置,这些布置虽然未在本文中明确描述或示出,但体现了本发明的原理并包括在其精神和范围内。此外,本文所陈述的所有实施例和条件语言主要旨在帮助读者理解本发明的原理和发明人为促进本领域所贡献的概念,并且应被解释为不限于这些特别叙述的实施例和条件。此外,本文叙述本发明的原理、方面和实施方案以及其具体实施例的所有陈述旨在涵盖其结构和功能等同物。另外,这些等同物旨在包括当前已知的等同物和将来开发的等同物,即,无论结构如何,都执行相同功能的所开发的任何元件。因此,本发明的范围不旨在限于本文示出和描述的示例性实施方案。相反,本发明的范围和精神由所附权利要求体现。
Claims (15)
1.一种制剂的用途,所述制剂用于增加对生酮饮食的依从性,所述制剂包括:
治疗有效剂量的芬氟拉明或其药学可接受盐、碱或酸;并且
其中所述用途是用于在多天时间段内向患者重复给药所述制剂,直至所述患者表现出对碳水化合物的渴望从基线降低。
2.根据权利要求1和2中任一项所述的用途,其中所述患者已经被诊断患有德拉韦综合征。
3.根据权利要求1至3中任一项所述的用途,其中所述用途是用于在多周时间段内使所述患者维持生酮饮食。
4.根据权利要求1至4中任一项所述的用途,其中所述用途是用于在多月时间段内使所述患者维持生酮饮食。
5.根据权利要求1至4中任一项所述的用途,其中所述患者已经被诊断患有难治性癫痫,所述难治性癫痫选自由德拉韦综合征、伦诺克斯-加斯托综合征和多泽综合征组成的组。
6.根据权利要求1-5中任一项所述的用途,其中所述制剂是用于与所述生酮饮食的各餐同时使用、在所述生酮饮食的各餐之前立即使用、或在所述生酮饮食的各餐之后立即使用。
7.根据权利要求1-6中任一项所述的用途,其中所述制剂包含三氯蔗糖、调味剂、缓冲剂、防腐剂和增稠剂。
8.根据权利要求1至7中任一项所述的用途,其中所述患者在18岁以下。
9.一种液体制剂,所述制剂包括:
治疗有效量的芬氟拉明活性剂;和
药学可接受媒介物,
其中所述制剂不含可消化的碳水化合物,并降低碳水化合物渴望,从而促进对生酮饮食的依从性;
其中所述芬氟拉明活性剂是芬氟拉明碱、或者其药学可接受盐或缀合物;其中所述制剂是包括三氯蔗糖、调味剂、缓冲剂、防腐剂和增稠剂的水性制剂。
10.根据权利要求9所述的液体芬氟拉明制剂,其中所述调味剂选自由樱桃调味剂、橙子调味剂、草莓调味剂、覆盆子、混合浆果、葡萄、橘子、甜柑及其组合组成的组。
11.根据权利要求10所述的液体芬氟拉明制剂,其中所述缓冲剂选自由柠檬酸钾一水合物、无水柠檬酸钾、磷酸钾、柠檬酸一水合物、无水柠檬酸及其组合组成的组。
12.根据权利要求11所述的液体芬氟拉明制剂,其中所述防腐剂选自由羟苯甲酯、羟苯乙酯、羟苯丙酯、山梨酸、山梨酸钾、苯甲酸钠、苯甲酸、丙酸及其组合组成的组。
13.根据权利要求12所述的液体芬氟拉明制剂,其中所述增稠剂选自由羟乙基纤维素、黄原胶、聚维酮、羟丙基纤维素、羟丙基甲基纤维素、共聚维酮、阿拉伯胶、瓜尔胶、槐豆胶、聚环氧乙烷及其组合组成的组。
14.一种液体芬氟拉明制剂,其包括:
盐酸芬氟拉明、浓度为2mg/mL的羟苯甲酯钠、浓度为0.2mg/mL的羟苯乙酯钠、浓度为1.0mg/mL的三氯蔗糖、浓度为5.0mg/mL的羟乙基纤维素、浓度为1.0mg/mL的樱桃调味粉、浓度为10.2mg/mL的柠檬酸钾一水合物、浓度为5.5mg/mL的柠檬酸一水合物、和水;
其中所述盐酸芬氟拉明以1.25mg/mL的浓度存在于所述制剂中。
15.根据权利要求9-14中任一项所述的制剂的用途,所述用途为用于治疗被诊断患有癫痫亚型的受试者;
其中所述用途是用于在多天时间段内向患者重复给药所述制剂,直至所述患者表现出对碳水化合物的渴望从基线降低,并从而使所述患者维持生酮饮食。
Applications Claiming Priority (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762563255P | 2017-09-26 | 2017-09-26 | |
US62/563,255 | 2017-09-26 | ||
US201762564225P | 2017-09-27 | 2017-09-27 | |
US62/564,225 | 2017-09-27 | ||
US201762579450P | 2017-10-31 | 2017-10-31 | |
US62/579,450 | 2017-10-31 | ||
US201762582173P | 2017-11-06 | 2017-11-06 | |
US62/582,173 | 2017-11-06 | ||
US201762593029P | 2017-11-30 | 2017-11-30 | |
US62/593,029 | 2017-11-30 | ||
US201862627329P | 2018-02-07 | 2018-02-07 | |
US62/627,329 | 2018-02-07 | ||
US201862669833P | 2018-05-10 | 2018-05-10 | |
US62/669,833 | 2018-05-10 | ||
US201862696801P | 2018-07-11 | 2018-07-11 | |
US62/696,801 | 2018-07-11 | ||
US16/140,120 | 2018-09-24 | ||
US16/140,120 US10682317B2 (en) | 2017-09-26 | 2018-09-24 | Ketogenic diet compatible fenfluramine formulation |
PCT/US2018/052567 WO2019067405A2 (en) | 2017-09-26 | 2018-09-25 | FORMULATION OF FENFLURAMINE COMPATIBLE WITH A CÉTOGENEOUS REGIMEN |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111971035A true CN111971035A (zh) | 2020-11-20 |
Family
ID=65806999
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880076100.9A Pending CN111971035A (zh) | 2017-09-26 | 2018-09-25 | 生酮饮食相容的芬氟拉明制剂 |
Country Status (8)
Country | Link |
---|---|
US (2) | US10682317B2 (zh) |
EP (1) | EP3687517A2 (zh) |
JP (1) | JP7213882B2 (zh) |
KR (1) | KR20200059274A (zh) |
CN (1) | CN111971035A (zh) |
AU (1) | AU2018341326A1 (zh) |
CA (1) | CA3077387A1 (zh) |
WO (1) | WO2019067405A2 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023034115A1 (en) * | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
US11634377B2 (en) | 2015-12-22 | 2023-04-25 | Zogenix International Limited | Fenfluramine compositions and methods of preparing the same |
US11673852B2 (en) | 2015-12-22 | 2023-06-13 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
US11759440B2 (en) | 2016-08-24 | 2023-09-19 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
US20230181512A1 (en) * | 2020-05-29 | 2023-06-15 | Cerecin Inc. | Methods for the treatment of infantile spasms using medium chain triglycerides |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452815A (en) * | 1980-06-16 | 1984-06-05 | Massachusetts Institute Of Technology | Method of utilizing d,l-fenfluramine for modifying feeding behavior |
WO2016138138A1 (en) * | 2015-02-25 | 2016-09-01 | The Regents Of The University Of California | 5ht agonists for treating disorders |
US20170056344A1 (en) * | 2015-08-24 | 2017-03-02 | Zogenix International Limited | Methods of treating lennox-gastaut syndrome using fenfluramine |
Family Cites Families (124)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR104F (zh) | 1960-11-05 | |||
US3117160A (en) | 1961-07-27 | 1964-01-07 | Pfizer & Co C | Aralkylamines |
US3198834A (en) | 1964-07-27 | 1965-08-03 | Snc Science Union Et Compagnie | Optical isomers of trifluoromethylated phenethylamines |
GB1254332A (en) | 1969-02-27 | 1971-11-17 | Science Union & Cie | Amino acids and their derivatives and processes for preparing them |
DE2143204C3 (de) | 1971-08-28 | 1979-09-27 | Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt | N-Fluoralkyl-phenylisopropylamin-Derivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel auf deren Basis |
DE2150399A1 (de) | 1971-10-09 | 1973-04-12 | Hoechst Ag | Neue oxime |
GB1413078A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of plus-norfenfluramine and plus-fenfluramine and salts thereof |
GB1413070A (en) | 1973-07-27 | 1975-11-05 | Beecham Group Ltd | Process for the production of - norfenfluramine and - fenfluramine and salts thereof |
US4309445A (en) | 1980-06-16 | 1982-01-05 | Massachusetts Institute Of Technology | d-Fenfluramine for modifying feeding behavior |
DE3717434C1 (de) | 1987-05-23 | 1988-09-15 | Degussa | Verfahren zur Herstellung von m-Trifluormethylphenylacetonitril |
KR890003368A (ko) | 1987-08-06 | 1989-04-14 | 원본미기재 | 특정의 치환된 페닐알킬아미노(및 아미노산) 유도체 및 기타 세로토닌농도 저하제로 오심 및 구토를 치료하는 방법 |
US4857553A (en) | 1987-08-06 | 1989-08-15 | A. H. Robins Company, Incorporated | Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents |
HU204497B (en) | 1989-10-09 | 1992-01-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing phenfluramine |
IT1238686B (it) | 1990-02-09 | 1993-09-01 | Lab Mag Spa | Procedimento per la preparazione di levo e destro fenfluramina |
FR2684552B1 (fr) | 1991-12-06 | 1995-04-28 | Adir | Utilisation de la d-fenfluramine et de derives de la fenfluramine dans le traitement de l'hypertension chez des sujets insulino-resistants. |
US5985880A (en) | 1996-06-05 | 1999-11-16 | Delta Pharmaceuticals | Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds |
WO1995004713A1 (en) | 1993-08-06 | 1995-02-16 | The Upjohn Company | 2-aminoindans as selective dopamine d3 ligands |
US5834477A (en) | 1993-12-08 | 1998-11-10 | The United States Of America As Represented By The Secretary Of The Army | Opiate analgesic formulation with improved safety |
US5412102A (en) | 1994-05-27 | 1995-05-02 | Syntex (U.S.A.) Inc. | Processes for preparing 1-butyl-2-[2'-(2H-tetrazol-5-yl) biphenyl-4-ylmethyl]-1H-indole-3-carboxylic acid |
WO1995033455A1 (en) | 1994-06-03 | 1995-12-14 | Elmaleh David R | Meta substituted arylalkylamines and therapeutic and diagnostic uses thereof |
IT1298349B1 (it) | 1996-05-29 | 2000-01-05 | Alfa Chem Ital | Processo per la produzione di 1 - (3-trifluorometil) fenil-propan- 2-one intermedio nella sintesi della fenfluramina |
IT1292885B1 (it) | 1997-04-28 | 1999-02-11 | Alfa Chem Ital | Processo per la produzione degli isomeri (r) ed (s)- alfa -metil-3- (trifluorometil)benzene-etanamina. |
EP0920864A1 (en) | 1997-12-03 | 1999-06-09 | Pfizer Products Inc. | Combination therapy including a specific beta-3 agonist and an anorectic agent |
US20020098175A1 (en) | 1998-06-16 | 2002-07-25 | Zohoungbogbo Mathias C. | Dietetic food composition and dietetic method using such composition |
US6045501A (en) | 1998-08-28 | 2000-04-04 | Celgene Corporation | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
CA2355293C (en) | 1998-12-23 | 2005-08-16 | Orphan Medical, Inc. | Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy |
US20080103179A1 (en) | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
US7124031B1 (en) | 2000-05-11 | 2006-10-17 | Medco Health Solutions, Inc. | System for monitoring regulation of pharmaceuticals from data structure of medical and labortory records |
US20020032581A1 (en) | 2000-07-17 | 2002-03-14 | Reitberg Donald P. | Single-patient drug trials used with accumulated database: risk of habituation |
US6315720B1 (en) | 2000-10-23 | 2001-11-13 | Celgene Corporation | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
CA2449613A1 (en) | 2001-06-22 | 2003-01-03 | Universite Catholique De Louvain | Hydrogel beads or capsules as artificial media for insects oviposition and rearing of endoparasitoids |
WO2003011306A1 (en) | 2001-07-31 | 2003-02-13 | Wyeth | Sucralose formulations to mask unpleasant tastes |
AUPR732601A0 (en) | 2001-08-28 | 2001-09-20 | Polychip Pharmaceuticals Pty Ltd | Methods for the synthesis of amines such as ephedrine and inter mediates |
RU2317104C2 (ru) | 2001-09-24 | 2008-02-20 | Импиэриэл Инноувейшнс Лимитид | Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения |
US7459432B2 (en) | 2001-09-24 | 2008-12-02 | Imperial College Innovations Ltd. | Modification of feeding behavior |
US6599901B1 (en) | 2001-11-19 | 2003-07-29 | Hoffman-La Roche Inc. | Pyridone substituted benzothiazole derivatives |
US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
EP1496838B1 (en) | 2002-03-12 | 2010-11-03 | Merck Sharp & Dohme Corp. | Substituted amides |
CA2479744A1 (en) | 2002-03-28 | 2003-10-09 | Paul E. Finke | Substituted 2,3-diphenyl pyridines |
US7668730B2 (en) | 2002-12-17 | 2010-02-23 | JPI Commercial, LLC. | Sensitive drug distribution system and method |
WO2005004865A1 (en) | 2003-07-08 | 2005-01-20 | Georg-August-Universität Göttingen | Use of 5-ht4(a)-serotonin receptor agonists |
GB0410266D0 (en) | 2004-05-07 | 2004-06-09 | Ketocytonyx Inc | Treatment of apoptosis |
US9820658B2 (en) | 2006-06-30 | 2017-11-21 | Bao Q. Tran | Systems and methods for providing interoperability among healthcare devices |
WO2006100676A2 (en) | 2005-03-21 | 2006-09-28 | Health-Smart Limited | System for continuous blood pressure monitoring |
EP1888030A1 (en) | 2005-05-25 | 2008-02-20 | Janssen Pharmaceutica N.V. | Pediatric formulation of topiramate |
JP2008546376A (ja) | 2005-06-16 | 2008-12-25 | バイオノミックス リミテッド | Scn1a遺伝子における変異を検出することによっててんかんを診断および処置するための方法 |
GB0515090D0 (en) | 2005-07-22 | 2005-08-31 | Birmingham Res & Dev Ltd | Novel epilepsy treatment |
WO2007031846A2 (en) | 2005-09-14 | 2007-03-22 | University Of The Witwatersrand, Johannesburg | Pharmaceutical composition |
DK2508621T3 (en) | 2005-11-29 | 2015-01-12 | Childrens Hosp Medical Center | Optimization and individualization of drug selection and dosage |
US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
BRPI0707518A2 (pt) | 2006-02-06 | 2011-05-10 | Novartis Ag | combinaÇço de compostos orgÂnicos |
DE102006030113B4 (de) | 2006-06-28 | 2009-02-12 | Chemische Fabrik Budenheim Kg | Graphitfreier Hochtemperatur-Schmierstoff |
JP2010501597A (ja) | 2006-08-31 | 2010-01-21 | ザ ガバナーズ オブ ザ ユニバーシティー オブ アルバータ | 正のアロステリックampa受容体モジュレーターを用いて呼吸抑制を阻害する方法 |
US20080243584A1 (en) | 2007-01-31 | 2008-10-02 | Quintiles Transnational Corp. | Methods and systems for allocating representatives to sites in clinical trials |
WO2008104524A1 (en) | 2007-02-28 | 2008-09-04 | Smithkline Beecham Corporation | Thiadiazole derivatives, inhibitors of stearoyl-coa desaturase |
GB2456183A (en) | 2008-01-04 | 2009-07-08 | Gw Pharma Ltd | Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament |
CA3066426A1 (en) | 2008-01-09 | 2009-07-16 | Charleston Laboratories, Inc. | Pharmaceutical compositions comprising an antiemetic and an opioid analgesic |
AU2009279372A1 (en) | 2008-08-06 | 2010-02-11 | Gosforth Centre (Holdings) Pty Ltd | Compositions and methods for treating psychiatric disorders |
WO2010020585A1 (en) | 2008-08-18 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin reuptake inhibitors for the treatment of rett syndrome |
AR073361A1 (es) | 2008-09-05 | 2010-11-03 | Gruenenthal Gmbh | Combinacion farmaceutica que comprende 3-(-3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico. uso |
US8386274B1 (en) | 2008-09-17 | 2013-02-26 | Mckesson Financial Holdings Limited | Systems and methods for a prescription safety network utilizing eligibility verification transactions |
CA2737391A1 (en) * | 2008-10-09 | 2010-04-15 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Liquid pharmaceutical formulation containing paracetamol |
EP2355818A4 (en) | 2008-10-10 | 2012-04-11 | Us Of America As Represented By The Secretary Of The Army On Behalf Of Walter Reed Army Inst Of Res | METHODS AND COMPOSITIONS FOR TREATING A CONDITION OF EPILEPTIC DISEASE AND EPILEPSY CRISES CAUSING EPILEPTIC DISEASE CONDITION |
TWI424832B (zh) | 2008-12-15 | 2014-02-01 | Proteus Digital Health Inc | 與身體有關的接收器及其方法 |
JP2012520130A (ja) | 2009-03-09 | 2012-09-06 | セルジーン コーポレーション | 薬に禁忌を示すであろう患者による薬へのアクセスを制限しながら患者へ薬を引き渡すための装置、及びその使用方法 |
JP5711724B2 (ja) | 2009-04-15 | 2015-05-07 | リサーチ・トライアングル・インスティチュート | モノアミン再取り込み阻害剤 |
WO2010124137A1 (en) | 2009-04-22 | 2010-10-28 | Millennium Pharmacy Systems, Inc. | Pharmacy management and administration with bedside real-time medical event data collection |
US9453027B2 (en) | 2009-07-27 | 2016-09-27 | Daljit Singh Dhanoa | Deuterium-enriched pyridinonecarboxamides and derivatives |
AR079862A1 (es) | 2010-01-08 | 2012-02-22 | Eurand Inc | Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion |
CA2792507C (en) | 2010-03-09 | 2018-05-22 | Perceptimed, Inc. | Medication verification and dispensing |
WO2011119227A2 (en) | 2010-03-25 | 2011-09-29 | Columbia Northwest Pharmaceuticals, Llc | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients |
JP2011221623A (ja) | 2010-04-06 | 2011-11-04 | Kakimori Suri | 在宅診療支援システム及び方法 |
JP2013526583A (ja) | 2010-05-21 | 2013-06-24 | リサーチ・トライアングル・インスティチュート | フェニルモルホリンおよびその類似体 |
EP2399513B1 (en) | 2010-06-23 | 2017-01-04 | Qatar University Qstp-B | System for non-invasive automated monitoring, detection, analysis, characterisation, prediction or prevention of seizures and movement disorder symptoms |
EP2598159A4 (en) | 2010-07-30 | 2014-01-08 | Merck Sharp & Dohme | INHIBITION OF CYP3A METABOLISM OF THE MEDICINAL PRODUCT |
KR20180118801A (ko) | 2010-09-01 | 2018-10-31 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 체중 관리에 유용한 5-ht2c 작동제의 변형-방출 투여 형태 |
US20120270848A1 (en) | 2010-10-22 | 2012-10-25 | Galleon Pharmaceuticals, Inc. | Novel Compositions and Therapeutic Methods Using Same |
US20140030343A1 (en) | 2010-10-26 | 2014-01-30 | Alpharma Pharmaceuticals Llc | Formulations and Methods for Attenuating Respiratory Depression Induced by Opioid Overdose |
RU103209U1 (ru) | 2010-10-29 | 2011-03-27 | Общество С Ограниченной Ответственностью "Правовое Сопровождение Бизнеса" | Клиническая информационная система |
GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
JP5693325B2 (ja) | 2011-03-29 | 2015-04-01 | 小林クリエイト株式会社 | 健診結果出力システム及び健診結果出力プログラム |
GB201111712D0 (en) | 2011-07-08 | 2011-08-24 | Gosforth Ct Holdings Pty Ltd | Pharmaceutical compositions |
US20140348966A1 (en) | 2011-12-22 | 2014-11-27 | Onesmo B. Balemba | Garcinia buchananii baker compounds, compositions and related methods |
US9346798B2 (en) | 2012-02-13 | 2016-05-24 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
US20130218586A1 (en) | 2012-02-21 | 2013-08-22 | Frederic J. Huser | Methods and elements for identifying the appropriate patient populations who can safely use prescription chronic care drugs that are switched to an over-the-counter regulatory status |
JP6075973B2 (ja) | 2012-06-04 | 2017-02-08 | 富士通株式会社 | 健康状態判定装置およびその作動方法 |
KR20150082633A (ko) | 2012-11-15 | 2015-07-15 | 갈레온 파마슈티칼스, 인코포레이티드 | 경구적으로 생체이용가능한 신규 호흡 조절 제어 화합물 및 그의 사용 방법 |
WO2014106825A2 (en) | 2013-01-06 | 2014-07-10 | Jonathan Rabinowitz | Methods and devices for identifying improper medical reporting |
US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
SI3035926T1 (sl) | 2013-08-19 | 2020-11-30 | The Regents Of The University Of California | Spojine in postopki za zdravljenje epileptičnih motenj |
WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
US20150141415A1 (en) | 2013-11-20 | 2015-05-21 | Omonike Arike Olaleye | Methionine Aminopeptidase Inhibitors for Treating Infectious Diseases |
CN103886415A (zh) | 2014-03-25 | 2014-06-25 | 北京蝶禾谊安信息技术有限公司 | 药品管理方法和装置 |
GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
BR112017006219A8 (pt) | 2014-09-29 | 2023-02-14 | Zogenix International Ltd | Sistema de controle para controle de distribuição de medicamentos |
GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
CN107427458A (zh) | 2015-02-06 | 2017-12-01 | 马瑞纳斯制药公司 | 静脉内加奈索酮制剂及其在治疗癫痫持续状态和其他癫痫发作病症中的用途 |
US10292996B2 (en) | 2015-03-26 | 2019-05-21 | The Trustees Of Columbia University In The City Of New York | Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome |
CA2989653A1 (en) | 2015-06-17 | 2016-12-22 | Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca | Nucleotide pools including mitochondrial dna depletion syndromes |
NO346258B1 (en) | 2015-06-30 | 2022-05-16 | Neurad Ltd | Novel breathing control modulating compounds, and methods of making and using same |
WO2017015309A1 (en) | 2015-07-22 | 2017-01-26 | John Hsu | Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof |
US20170071949A1 (en) | 2015-09-14 | 2017-03-16 | Zogenix International Limited | Combination treatment of specific forms of epilepsy |
EP3170807B1 (en) | 2015-11-23 | 2019-12-11 | Frau Pharma S.r.l. | New method for synthesis of fenfluramine |
KR20180095674A (ko) | 2015-12-22 | 2018-08-27 | 조게닉스 인터내셔널 리미티드 | 대사 저항성 펜플루라민 유사체 및 그 사용 방법 |
CN108883399B (zh) | 2015-12-22 | 2021-06-22 | 周格尼克斯国际有限公司 | 芬氟拉明组合物及其制备方法 |
JP6753418B2 (ja) | 2016-01-14 | 2020-09-09 | Agc株式会社 | フッ素樹脂含有溶液、フッ素樹脂含有溶液の製造方法、塗料組成物および塗装物品 |
WO2018037306A1 (en) | 2016-08-24 | 2018-03-01 | Zogenix International Limited | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
US20180092864A1 (en) | 2016-09-30 | 2018-04-05 | Zogenix International Limited | Compositions and methods for treating seizure disorders |
AU2018265353A1 (en) | 2017-05-09 | 2019-11-21 | Zogenix International Limited | Methods of treating Doose syndrome using fenfluramine |
US10682317B2 (en) | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
US20190091179A1 (en) | 2017-09-26 | 2019-03-28 | Zogenix International Limited | Congnitive function with fenfluramine |
WO2019067413A1 (en) | 2017-09-26 | 2019-04-04 | Zogenix International Limited | USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS |
KR20210009317A (ko) | 2018-04-18 | 2021-01-26 | 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 | 미토콘드리아 dna 고갈 증후군을 포함하는 불균형 뉴클레오타이드 풀에 의해 초래된 질환에 대한 유전자 요법 |
WO2019216919A1 (en) | 2018-05-11 | 2019-11-14 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
WO2019241005A1 (en) | 2018-06-14 | 2019-12-19 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
JP2021530481A (ja) | 2018-07-10 | 2021-11-11 | ゾゲニクス インターナショナル リミテッド | 肺高血圧症を有さない患者においててんかんまたはてんかん性脳症を処置するために使用するためのフェンフルラミン |
EA202191079A1 (ru) | 2018-11-19 | 2021-09-20 | Зодженикс Интернэшнл Лимитед | Способы лечения синдрома ретта с применением фенфлурамина |
EP3887481A4 (en) | 2018-11-30 | 2022-08-03 | Zogenix International Limited | METHODS OF TREATMENT OF REFRACTORY EPILEPSY SYNDROMES USING FENFLURAMINE ENANTIOMERS |
US20220133652A1 (en) | 2019-02-25 | 2022-05-05 | Zogenix International Limited | A formulation for improving seizure control |
US20210299064A1 (en) | 2020-02-05 | 2021-09-30 | Zogenix International Limited | Method of treating patients with lennox-gastaut syndrome |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
US20220096514A1 (en) | 2020-09-29 | 2022-03-31 | Zogenix International Limited | Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine |
-
2018
- 2018-09-24 US US16/140,120 patent/US10682317B2/en active Active
- 2018-09-25 CN CN201880076100.9A patent/CN111971035A/zh active Pending
- 2018-09-25 JP JP2020538761A patent/JP7213882B2/ja active Active
- 2018-09-25 AU AU2018341326A patent/AU2018341326A1/en not_active Abandoned
- 2018-09-25 CA CA3077387A patent/CA3077387A1/en active Pending
- 2018-09-25 KR KR1020207012003A patent/KR20200059274A/ko unknown
- 2018-09-25 WO PCT/US2018/052567 patent/WO2019067405A2/en unknown
- 2018-09-25 EP EP18811957.2A patent/EP3687517A2/en not_active Withdrawn
-
2020
- 2020-05-04 US US16/866,083 patent/US11458111B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452815A (en) * | 1980-06-16 | 1984-06-05 | Massachusetts Institute Of Technology | Method of utilizing d,l-fenfluramine for modifying feeding behavior |
WO2016138138A1 (en) * | 2015-02-25 | 2016-09-01 | The Regents Of The University Of California | 5ht agonists for treating disorders |
US20170056344A1 (en) * | 2015-08-24 | 2017-03-02 | Zogenix International Limited | Methods of treating lennox-gastaut syndrome using fenfluramine |
Non-Patent Citations (4)
Title |
---|
樊德厚等主编: "《中国药物大全》", 31 January 1998, 人民卫生出版社 * |
汪多仁主编: "《合成树脂与工程塑料生产技术》", 31 August 2001, 中国轻工业出版社 * |
潘道东主编: "《功能性食品添加剂》", 31 January 2006, 中国轻工业出版社 * |
王丽主编: "《小儿癫痫——现代概念与临床治疗》", 31 January 1995, 北京医科大学、中国协和医科大学联合出版社 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11634377B2 (en) | 2015-12-22 | 2023-04-25 | Zogenix International Limited | Fenfluramine compositions and methods of preparing the same |
US11673852B2 (en) | 2015-12-22 | 2023-06-13 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
US11759440B2 (en) | 2016-08-24 | 2023-09-19 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
US11786487B2 (en) | 2016-08-24 | 2023-10-17 | Zogenix International Limited | Formulation for inhibiting formation of 5-HT2B agonists and methods of using same |
US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
WO2023034115A1 (en) * | 2021-09-01 | 2023-03-09 | Zogenix International Limited | Fenfluramine for treatment of demyelinating diseases and conditions |
Also Published As
Publication number | Publication date |
---|---|
KR20200059274A (ko) | 2020-05-28 |
RU2020112113A3 (zh) | 2022-01-28 |
US20190091178A1 (en) | 2019-03-28 |
EP3687517A2 (en) | 2020-08-05 |
RU2020112113A (ru) | 2021-10-27 |
JP7213882B2 (ja) | 2023-01-27 |
WO2019067405A2 (en) | 2019-04-04 |
US11458111B2 (en) | 2022-10-04 |
WO2019067405A3 (en) | 2019-05-02 |
AU2018341326A1 (en) | 2020-04-09 |
CA3077387A1 (en) | 2019-04-04 |
JP2020535227A (ja) | 2020-12-03 |
US10682317B2 (en) | 2020-06-16 |
US20200261380A1 (en) | 2020-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11458111B2 (en) | Ketogenic diet compatible fenfluramine formulation | |
US9089528B2 (en) | Liquid compositions of calcium acetate | |
Peña-Quintana et al. | Profile of sodium phenylbutyrate granules for the treatment of urea-cycle disorders: patient perspectives | |
TW200936144A (en) | Protopanaxadiol-type ginsenoside compositions and uses thereof | |
KR101490721B1 (ko) | 감칠맛을 가진 디페리프론용 액상 제제 | |
US11806334B1 (en) | Non-sedating dexmedetomidine treatment regimens | |
US20240100029A1 (en) | Treatment of migraine | |
TWI708606B (zh) | 格拉匹綸(grapiprant)組合物及其使用方法 | |
US20230149318A1 (en) | Combinations of nanoparticle-encapsulated cargo entities and methods for making and using same | |
JP5211677B2 (ja) | 内服液剤 | |
RU2778848C2 (ru) | Состав фенфлурамина, совместимый с кетогенной диетой | |
US10986857B2 (en) | Dietary supplementation with mixed alkali salts | |
WO2011034006A1 (ja) | 血液中の尿酸値を低下させるための組成物 | |
NL2024160B1 (en) | Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition | |
WO2024058812A1 (en) | Vigabatrin liquid pharmaceutical composition | |
JP2020093984A (ja) | アルコール依存症の予防薬 | |
Al-Nawafleh et al. | Herpes Gestations: A Case Report | |
AU2013202958A1 (en) | Liquid Compositions of Calcium Acetate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40038071 Country of ref document: HK |
|
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201120 |